# **Supporting Information**

# *De Novo* Synthesis, Structural Assignment and Biological Evaluation of Pseudopaline, a Metallophore Produced by *Pseudomonas aeruginosa*

Jian Zhang,<sup>1,3</sup> Tianhu Zhao,<sup>1,3</sup> Rongwen Yang,<sup>1,3</sup> Ittipon Siridechakorn,<sup>1</sup> Sanshan Wang,<sup>1</sup> Qianqian Guo,<sup>1</sup> Yingjie Bai,<sup>1</sup> Hong C. Shen,<sup>2</sup> Xiaoguang Lei<sup>1\*</sup>

<sup>1</sup>Department of Chemical Biology, College of Chemistry and Molecular Engineering, Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, Synthetic and Functional Biomolecules Center and Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China, <sup>2</sup> Roche Innovation Center Shanghai, Roche Pharma Research & Early Development, Shanghai 201203, China, <sup>3</sup>These authors contributed equally, \*Correspondence: xglei@pku.edu.cn

# **Table of Contents**

I) General Information	S3
II) Detailed synthetic procedures	S4-S18
III) Comparison of the synthetic and natural Fmoc-pseudopaline	\$19-\$22
IV) Biological evaluations	S23-S24
V) Metal chelation experiments	S25-S29
VI) NMR spectra	\$30-\$73
VII) HRMS data for the metal chelation experiments	S74-S91
VIII) X-ray crystal structures	\$92-\$95
IX) References	S96


## I) General Information

<sup>1</sup>H NMR spectra were recorded on a Bruker 400 MHz spectrometer at ambient temperature with CDCl<sub>3</sub> as the solvent unless otherwise stated. <sup>13</sup>C NMR spectra were recorded on a Bruker 101 MHz or 126 MHz spectrometer (with complete proton decoupling) at ambient temperature. <sup>13</sup>C NMR spectra of synthetic Fmoc-pseudopaline and natural Fmoc-pseudopaline were recorded on a Bruker AVANCE 201 MHz spectrometer (with complete proton decoupling) at ambient temperature. <sup>13</sup>C NMR spectrum of compound **16** was recorded on a Bruker AVANCE 239 MHz spectrometer (with complete proton decoupling) at ambient temperature. Chemical shifts are reported in parts per million relative to chloroform (<sup>1</sup>H, δ 7.26 ppm; <sup>13</sup>C, δ 77.00 ppm) or deuterium oxide (<sup>1</sup>H, δ 4.79 ppm). Data for <sup>1</sup>H NMR is reported as follow: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet) and coupling constants. IR spectra were recorded on a Thermo Fisher FT-IR200 spectrophotometer. High-resolution mass spectra were obtained at Peking University Mass Spectrometry Laboratory using a Bruker Fourier Transform Ion Cyclotron Resonance Mass Spectrometer Solarix XR. Optical rotations were recorded on an AUTOPOL III digital polarimeter at 589 nm as [a]<sup>20</sup> (concentration in grams/100 mL solvent). The samples were analyzed by HPLC/MS on a Waters Auto Purification LC/MS system (3100 Mass Detector, 2545 Binary Gradient Module, 2767 Sample Manager, and 2998 Photodiode Array (PDA) Detector). The system was equipped with a Waters C18 5 µm SunFire separation column (150\*4.6 mm), equilibrated with HPLC grade water (solvent A) and HPLC grade methanol (solvent B) with a flow rate of 0.3 mL/min at rt. Preparative HPLC-MS on a Waters Auto Purification LC/MS system (3100 Mass Detector, 2545 Binary Gradient Module, 515 HPLC pump, 2767 Sample Manager, and 2998 Photodiode Array (PDA) Detector). The system was equipped with a Waters C18 5µm X-bridge separation column (150\*19 mm). Analytical thin layer chromatography was performed using 0.25 mm silica gel 60-F plates. Flash chromatography was performed using 200-400 mesh silica gel. Yields refer to chromatographically and spectroscopically pure materials, unless otherwise stated. All reagents were used as supplied by Sigma-Aldrich, J&K and Alfa Aesar Chemicals. All reactions were carried out in oven-dried glassware under an argon atmosphere unless otherwise noted.

## **II)** Detailed Experimental Section


#### Syntheses of the building blocks

Compound 12




To a stirred solution of **SM** (15 g, 59 mmol, 1 eq) in  $H_2O$  (100 mL) and acetone (125 mL) at 0 °C was added NaHCO<sub>3</sub> (12.9 g, 153 mmol, 2.6 eq) and CbzCl (10 mL, 71 mmol, 1.2 eq). After stirring for 2 h at 0 °C, acetone was removed *in vacuo*, then added sat. KHSO<sub>4</sub> to pH=1-2. The water phase was extracted by EA (100 mL x 2). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated *in vacuo*. To the residue was added DMF (100 mL), K<sub>2</sub>CO<sub>3</sub> (12.2 g, 88 mmol, 1.5 eq) and BnBr (7.4 mL, 62 mmol, 1.05 eq), and the resulting mixture was stirred for 12 h. then added EA (300 mL) and H<sub>2</sub>O (100 mL), the organic phase was washed with brine (50 mL x 3) and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated *in vacuo*, and the crude product was purified by recrystallization from hexane: DCM to afford the product **12** as a white solid (21.2 g, 44.3 mmol, 75%).

Compound 6



To a stirred solution of compound **12** (21.2 g, 44.3 mmol, 1 eq) in DCM (132 mL) at 0 °C was added TFA (14.7 mL). After stirring for 1 h at room temperature, the solvent was removed *in vacuo*. To the residue was added EA (110 mL), NsCl (10.8 g, 48.7 mmol, 1.1 eq) and a solution of NaHCO<sub>3</sub> (14.9 g, 177.2 mmol, 4 eq) in H<sub>2</sub>O (110 mL), and the resulting mixture was stirred for 12 h. The organic phase was washed with aq. NaHCO<sub>3</sub> (100 mL x 2), brine (100 mL x 1) and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated *in vacuo*, and the crude product was purified by recrystallization from hexane: DCM to afford the product as a white solid (21.7 g, 38.5 mmol, 87%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.00 – 7.96 (m, 2H), 7.75 – 7.66 (m, 1H), 7.60 – 7.52 (m, 2H), 7.46 – 7.38 (m, 5H), 7.25 – 7.19 (m, 3H), 7.12 – 7.09 (m, 3H), 7.05 (s, 1H), 5.38 (s, 2H), 4.93 (d, *J* = 12.0 Hz, 1H), 4.82 (d, *J* = 12.0 Hz, 1H), 4.65 – 4.61 (m, 1H), 3.12 – 3.09 (m, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.1, 148.2, 147.4, 138.1, 137.0, 134.9, 133.9, 133.1, 132.6, 130.3, 129.3, 128.9, 128.4, 128.3, 125.3, 114.9, 69.9, 67.2, 56.2, 31.0; IR (neat) v<sub>max</sub> 1683, 1515, 1387, 1362, 1319, 1148, 928 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>25</sub>N<sub>4</sub>O<sub>8</sub>S: 565.1388, found: 565.1381; [α]<sub>0</sub><sup>23</sup> –88.6 (*c* 0.5, CHCl<sub>3</sub>); m.p. = 125-130°C; R<sub>f</sub> = 0.52 (DCM/MeOH = 40/1 with 1/1000 ammonium hydroxide).



homoserine Y-lactone byproduct

Scheme S1: Initial Synthesis of the Homoserine Building Block 8

#### Compound 10a

To a stirred solution of **10** (3.26 g, 10.5 mmol, 1 eq) in DCM (24 mL) at 0 °C was added TFA (6 mL). After stirred for 1 h at r.t., the solvent was removed *in vacuo*. To the residue was added EA (20 mL), NsCl (2.35 g, 10.6 mmol, 1.01 eq) and saturated NaHCO<sub>3</sub> (30 mL), and the resulting mixture was stirred for 12 h. The organic phase was washed with aq. NaHCO<sub>3</sub> (20 mL x 2), brine (10 mL x 1) and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated *in vacuo*, and the crude product was purified by silica gel column chromatography (PE/EA=10:1 to 8:1) to afford product **10a** (1.19 g, 3.05 mmol, 29%) as white oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.02 – 7.99 (m, 1H), 7.82 – 7.80 (m, 1H), 7.64 – 7.59 (m, 2H), 7.32 – 7.29 (m, 3H), 7.17 – 7.15 (m, 2H), 6.54 (d, *J* = 8.8 Hz, 1H), 4.96 (d, *J* = 12.1 Hz, 1H), 4.91 (d, *J* = 12.1 Hz, 1H), 4.43 (td, *J* = 8.7, 4.3 Hz, 1H), 3.85 – 3.79 (m, 2H), 2.20 – 2.13 (m, 1H), 1.99 – 1.88 (m, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  171.0, 147.4, 134.7, 133.8, 133.5, 132.8, 130.3, 128.5, 128.3, 125.6, 67.4, 58.2, 54.2, 35.0; IR (neat) v<sub>max</sub> 3329, 2925, 1741, 1540, 1356, 1167, 1119 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>19</sub>N<sub>2</sub>O<sub>7</sub>S: 395.0906, found: 395.0907; [α]<sup>24</sup><sub>D</sub> – 173 (c 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.22 (PE/EA = 2/1).

#### Compound 8

Compound **10a** (1.19 g, 3.02 mmol, 1.0 eq) was dissolved in DCM (10 mL) and to this solution was added imidazole (308 mg, 4.53 mmol, 1.5 eq) and TBSCI (569 mg, 3.78 mmol, 1.25 eq) at 0 °C under argon. The mixture was warmed to r.t. and stirred for 1 h. The reaction was quenched by water (10 mL) at 0 °C, and the water phase was extracted by DCM (10 mL x 3). The combined organic

phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (PE/EA = 20/1) to afford the desired product **8** (1.38 g, 2.72 mmol, 90%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.98 (d, *J* = 7.6 Hz, 1H), 7.78 (d, *J* = 7.6 Hz, 1H), 7.62 – 7.57 (m, 2H), 7.32 – 7.30 (m, 3H), 7.22 – 7.13 (m, 2H), 6.48 (d, *J* = 8.8 Hz, 1H), 4.95 (d, *J* = 12.0 Hz, 1H), 4.86 (d, *J* = 12.0 Hz, 1H), 4.47 – 4.42 (m, 1H), 3.77 – 3.70 (m, 2H), 2.14 – 1.99 (m, 2H), 0.90 (s, 9H), 0.06 (s, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.9, 147.5, 134. 9, 134.4, 133.3, 132.6, 130.3, 128.5, 128.4, 128.2, 125.4, 67.1, 59.0, 54.7, 35.2, 25.9, 18.3, -5.6; IR (neat) v<sub>max</sub> 3329, 2957, 2857, 1745, 1542, 1368, 1172, 1122, 837 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>32</sub>N<sub>2</sub>O<sub>7</sub>SSi:


509.1772, found: 509.1768;  $[\alpha]_{D}^{24}$ -110 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.67 (PE/EA = 2/1).

#### Compound 11



Compound **10** (7.8 g, 25.2 mmol, 1.0 eq) was dissolved in DCM (126 mL) and to this solution was added imidazole (2.58 g, 37.8 mmol, 1.5 eq) and TBSCI (4.76 g, 31.6 mmol, 1.25 eq) at 0 °C under argon. The mixture was stirred for 1 h at 0 °C. Then the reaction was quenched by water (50 mL) at 0 °C, the water phase was extracted by DCM (100 mL x 3). The combined organic phases were dried and concentrated *in vacuo*. The residue was further purified by silica gel column chromatography (PE/EA = 20/1) to afford the desired product **11** (9.1 g, 23.4 mmol, 93%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.35 – 7.29 (m, 5H), 5.76 (d, *J* = 7.5 Hz, 1H), 5.21 (d, *J* = 12.4 Hz, 1H), 5.11 (d, *J* = 12.4 Hz, 1H), 4.42 (dd, *J* = 11.6, 7.0 Hz, 1H), 3.71 – 3.61 (m, 2H), 2.11 – 1.98 (m, 1H), 1.94 (dd, *J* = 12.9, 7.4 Hz, 1H), 1.42 (s, 9H), 0.88 (s, 9H), 0.02 (s, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  172.4, 155.6, 135.7, 128.5, 128.3, 128.2, 79.5, 66.8, 60.2, 52.6, 33.7, 28.3, 25.9, 25.7, 18.1, -5.6, -5.7; IR (neat) v<sub>max</sub> 2916, 1723, 1496, 1460, 1378, 1159, 836, 730 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>22</sub>H<sub>38</sub>NO<sub>5</sub>Si: 424.2514 found: 424.2528; [ $\alpha$ ]<sup>21</sup> -25.4 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.80 (PE/EA = 3/1).

Compound 8



TMSOTf (18.8 mL, 98.7 mmol, 8.0 eq) was added to a stirring solution of compound **11** (5.23 g, 12.3 mmol, 1.0 eq) in DCM (61.5 mL) in the presence of 2,6-lutidine (14.3 mL, 123.0 mmol, 10.0 eq) at r.t.. After 1.5 h, MeOH (20 mL) was added to the reaction mixture at 0 °C, then warmed to r.t. and stirred for 2 h. The reaction mixture was concentrated *in vacuo* to afford colorless oil, which was immediately used for the next reaction without further purification. NsCl (3.27 g, 14.8 mmol, 1.2 eq) was added in one portion to a stirring EA (30 mL) solution of the crude amine at r.t.. A solution of NaHCO<sub>3</sub> (5.46 g, 65 mmol, 5.0 eq,) in 31.5 mL H<sub>2</sub>O was added to the mixture. After stirring for 12 h, the mixture was diluted with EA (100 mL), and the water layer was separated. The organic layer was concentrated *in vacuo* to afford a residue, which was purified by silica gel column chromatography (PE/EA 30/1) to afford compound **8** (4.50 g, 8.9 mmol, 72%) as a colorless oil.

#### The Asymmetric Tsuji-Trost reaction

#### General procedure:

Preparation of these substrates: The amino group was firstly protected by NsCl using EA and aq. NaHCO<sub>3</sub> as co-solvent. The carboxylic acid was protected by BnBr using NaHCO<sub>3</sub> as base and DMF as solvent.

For the asymmetric Tsuji-Trost reaction: to a solution of  $Pd_2(dba)_3$ ·CHCl<sub>3</sub>(5.2 mg, 0.005 mmol, 0.05 eq) and Trost-ligand (11.9 mg, 0.015 mmol, 0.15 eq) in THF (1 mL) was added compound **9** (42.6 mg, 0.3 mmol, 3 eq) and TEA (30.3 mg, 0.3 mmol, 3 eq) at 0 °C. Then a solution of **SM** (0.1 mmol, 1 eq) in THF (1 mL) was added into the mixture. The reaction was monitored by TLC. The reaction mixture was concentrated *in vacuo* and the residue was purified by silica gel column chromatography (PE/EA=10/1 to 8/1) to afford the desired product.

Compound 7c, 91% yield, d.r.>20:1, white solid


Single crystals with X-ray diffraction quality were grown by dissolving the material in DCM and n-hexane. The mixture was lightly capped and the solvents were allowed to slowly evaporate.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.06 (s, 1H), 8.03 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.58 – 7.45 (m, 3H), 7.44 – 7.41 (m, 5H), 7.31 – 7.28 (m, 3H), 7.26 – 7.23 (m, 2H), 7.18 (s, 1H), 5.96 (dd, *J* = 5.6, 2.4 Hz, 1H), 5.60 (dd, *J* = 5.6, 2.4 Hz, 1H), 5.40 (d, *J* = 11.6 Hz, 1H), 5.37 (d, *J* = 11.6 Hz, 1H), 5.11 (d, *J* = 12 Hz, 1H), 5.04 (d, *J* = 12 Hz, 1H), 4.90 – 4.85 (m, 1H), 4.66 (t, *J* = 6.8 Hz, 1H), 3.59 (dd, *J* = 14.8 Hz, 7.0 Hz, 1H), 3.16 (d, *J* = 14.8 Hz, 7.0 Hz, 1H), 2.61 – 2.55 (m, 1H), 2.30 – 2.07 (m, 2H), 1.72 - 1.67 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.5, 148.6, 148.4, 139.8, 136.9, 136.6, 135.1, 134.6, 134.0, 133.2, 131.3, 130.8, 129.3, 129.2, 128.9, 128.8, 128.5, 128.4, 123.9,

115.1, 69.8, 67.6, 66.4, 58.4, 31.4, 31.2, 28.8; IR (neat)  $v_{max}$  2958, 1757, 1544, 1405, 1243, 1213, 1012 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>32</sub>H<sub>31</sub>N<sub>4</sub>O<sub>8</sub>S: 631.1857, found: 631.1855; [ $\alpha$ ]<sup>22</sup><sub>D</sub> –30.4 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> =0.55(DCM/MeOH = 40/1 with 1/1000 ammonium hydroxide); m.p. =146-149°C.


#### Substrate for Compound 7d, white oil

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.95 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.79 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.64 – 7.54 (m, 2H), 7.36 – 7.30 (m, 8H), 7.15 – 7.13 (m, 2H), 6.24 (d, *J* = 9.1 Hz, 1H), 5.13 (s, 2H), 4.94 – 4.83 (m, 2H), 4.31 (td, *J* = 9.1, 4.7 Hz, 1H), 2.64 – 2.50 (m, 2H), 2.32 – 2.24 (m, 1H), 2.08 – 1.92 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  172.2, 170.4, 147.5, 135.7, 134.6, 133.8, 133.6, 132.8, 130.3, 128.6, 128.6, 128.3, 128.3, 128.3, 125.6, 67.5, 66.6, 56.0, 29.7, 28.1; IR (neat) v<sub>max</sub> 3358, 2954, 1740, 1539, 1355, 1169 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>24</sub>H<sub>26</sub>N<sub>3</sub>O<sub>8</sub>S: 516.1435, found: 516.1449; [ $\alpha$ ]<sup>22</sup><sub>2</sub> -132.0 (*c* 2, CHCl<sub>3</sub>); R<sub>f</sub> = 0.32 (PE/EA = 2/1).



#### Compound 7d, 97% yield, d.r.>20:1, colorless oil


<sup>1</sup>H NMR (400 MHz,  $\dot{C}DCl_3$ )  $\delta$  8.07 – 7.97 (m, 1H), 7.77 – 7.67 (m, 1H), 7.64 – 7.56 (m, 2H), 7.41 – 7.26 (m, 8H), 7.10 – 7.04 (m, 2H), 6.75 (d, *J* = 9.0 Hz, 1H), 5.10 (s, 2H), 4.87 (dd, *J* = 31.3, 12.1 Hz, 2H), 4.53 (dt, *J* = 9.0, 4.5 Hz, 1H), 3.18 (dd, *J* = 17.3, 4.4 Hz, 1H), 2.97 (dd, *J* = 17.3, 4.6 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.2, 169.6, 147.4, 135.0, 134.4, 134.3, 133.4, 132.7, 130.2, 128.6, 128.6, 128.5, 128.5, 128.5, 128.3, 125.6, 67.9, 67.2, 53.2, 38.0; IR (neat) v<sub>max</sub> 3033, 2917, 1734, 1543, 1341, 1160 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>29</sub>H<sub>32</sub>N<sub>3</sub>O<sub>8</sub>S: 582.1904, found: 582.1907; [a]<sub>2</sub><sup>2</sup> - 75.9 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.42 (PE/EA = 2/1).



To a solution of the alcohol **13a** (28 mg, 0.06 mmol) in DCM (1mL) was added Dess-Martin reagent (38 mg, 0.09 mmol 1.5 eq) at 0  $^{\circ}$ C, then the reaction mixture was warmed to room temperature and stirred for 2.5 h, then cooled to 0  $^{\circ}$ C, and quenched with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (1 mL) and saturated NaHCO<sub>3</sub> (1 mL). The resulting mixture was warmed up to room temperature again and stirred for an additional 1 h. The resulting solution was extracted with DCM (10 mL × 3), then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and the filtrate was concentrated *in vacuo* to afford the crude aldehyde which was directly used for the next step without further purification.

To a cooled (0 °C) stirred solution of the intermediate aldehyde in 5.1.2 *t*-BuOH/2-methyl-2-butene (1.4 mL) was added an ice-cold buffered 1.1 M aqueous solution of NaClO<sub>2</sub> (0.27 mL, 0.3 mmol 5 eq) dropwise. The reaction mixture was stirred for 3 h and then quenched with pH=2 KH<sub>2</sub>PO<sub>4</sub>-HCl buffer (1 mL). The mixture was extracted with EA (10 mL × 3) and dried (MgSO<sub>4</sub>), filtered and evaporated under reduced pressure to give colorless oil. The product was used without further purification.

To the residue in DMF (1 mL) was added NaHCO<sub>3</sub> (15.1 mg, 0.18 mmol, 3 eq) and BnBr (7.8  $\mu$ L, 0.066 mmol, 1.1 eq), the mixture was stirred for 12 h at room temperature. The mixture was quenched with water (2 mL), and extracted with EA (10 mL x 2). The organic phase was washed with brine (2 mL x 2), dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (PE/EA = 10/1) to afford the desired product **7d** (22 mg, 0.039 mmol, 65%) as colorless oil. <sup>1</sup>H NMR was provided.



#### Substrate for Compound 7e, white oil


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.95 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.79 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.64 – 7.54 (m, 2H), 7.36 – 7.30 (m, 8H), 7.15 – 7.13 (m, 2H), 6.24 (d, *J* = 9.1 Hz, 1H), 5.13 (s, 2H), 4.94 – 4.83 (m, 2H), 4.31 (td, *J* = 9.1, 4.7 Hz, 1H), 2.64 – 2.50 (m, 2H), 2.32 – 2.24 (m, 1H), 2.08 – 1.92 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  172.2, 170.4, 147.5, 135.7, 134.6, 133.8, 133.6, 132.8, 130.3, 128.6, 128.6, 128.3, 128.3, 128.3, 125.6, 67.5, 66.6, 56.0, 29.7, 28.1; IR (neat) v<sub>max</sub> 3319, 2955, 1735, 1540, 1355, 1169, 970 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>25</sub>H<sub>28</sub>N<sub>3</sub>O<sub>8</sub>S: 530.1591, found: 530.1592; [ $\alpha$ ]<sup>22</sup><sub>2</sub> – 141.2 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.45 (PE/EA = 2/1).

#### Compound 7e, 80% yield, d.r.>20:1, colorless oil

<sup>1</sup>H NMR (400 MHz,  $\dot{C}DC_{3}$ )  $\delta$  8.10 – 8.04 (m, 1H), 7.63 – 7.51 (m, 2H), 7.49 – 7.43 (m, 1H), 7.38 – 7.24 (m, 10H), 6.10 – 5.96 (m, 1H), 5.66 – 5.51 (m, 1H), 5.16 – 4.96 (m, 4H), 4.91 – 4.83 (m, 1H), 4.78 (dd, *J* = 9.4, 3.6 Hz, 1H),  $\delta$  3.54 (dd, *J* = 16.7, 9.4 Hz, 1H), 2.79 (dd, *J* = 16.7, 3.8 Hz, 1H), 2.55 – 2.39 (m, 1H), 2.32 – 2.17 (m, 2H), 1.85 – 1.72 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.5, 137.4, 134.8,  $\delta$  133.6, 133.5, 131.5, 130.7, 129.0, 128.4, 128.3, 128.3, 128.2, 128.2, 124.0, 67.9, 66.9, 66.0, 54.7, 38.1, 31.2, 28.7. IR (neat) v<sub>max</sub> 2925, 1734, 1543, 1372, 1348, 1259, 1160 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>30</sub>H<sub>30</sub>N<sub>2</sub>O<sub>8</sub>S: 596.2061, found: 596.2059; [ $\alpha$ ]<sub>22</sub><sup>22</sup> +7.0 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.55 (PE/EA = 2/1).

#### Compound 21a. colorless oil

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.00 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.81 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.68 – 7.58 (m, 2H), 7.35 – 7.31 (m, 3H), 7.22 – 7.09 (m, 2H), 6.15 (d, *J* = 8.6 Hz, 1H), 4.97 – 4.90 (m, 2H), 4.34 – 4.26 (m, 1H), 1.50 (d, *J* = 7.2 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  171.3, 147.6, 142.4, 134.7, 133.5, 132.8, 130.3, 128.6, 128.6, 128.2, 125.6, 67.4, 52.6, 19.8; IR (neat) v<sub>max</sub> 3325, 2916, 1741, 1540, 1353, 1172, 1123 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>16</sub>H<sub>20</sub>N<sub>3</sub>O<sub>6</sub>S: 382.1067, found: 382.1066; [α]<sub>D</sub><sup>2</sup>-176.1 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.31 (PE/EA = 2/1).



#### Compound 7f, 95% yield, d.r.>20:1, colorless oil

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.10 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.62 – 7.59(m, 1H), 7.55 – 7.50 (m, 2H), 7.36 – 7.28 (m, 5H), 5.98 – 5.94 (m, 1H), 5.60 – 5.56 (m, 1H), 5.15 (d, *J* = 12.2 Hz, 1H), 5.09 (d, *J* = 12.2 Hz, 1H), 4.74 – 4.71 (m, 1H), 4.56 (q, *J* = 7.2 Hz, 1H), 2.57 – 2.50 (m, 1H), 2.32 – 2.21 (m, 2H), 1.97 – 1.90 (m, 1H), 1.66 (d, *J* = 7.2 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  171.6, 148.5, 136.1, 135.2, 134.8, 133.3, 133.1, 131.3, 131.0, 129.6, 128.5, 128.4, 128.3, 123.9, 67.4, 65.7, 55.3, 31.5, 29.7, 18.3; IR (neat) v<sub>max</sub>2947, 1741, 1543, 1372, 1342, 1160, 1126 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>21</sub>H<sub>26</sub>N<sub>3</sub>O<sub>6</sub>S: 448.1537, found: 448.1535; [α]<sub>2</sub><sup>22</sup> -29.5 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.43 (PE/EA = 2/1).

#### Substrate for compound **7g**, colorless oil

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.00 (dd, *J* = 7.6, 1.4 Hz, 1H), 7.82 (dd, *J* = 7.6, 1.4 Hz, 1H), 7.67 – 7.59 (m, 2H), 7.33 – 7.32 (m, 3H), 7.22 – 7.18 (m, 2H), 6.12 (d, *J* = 8.9 Hz, 1H), 5.69 – 5.59 (m, 1H), 5.13 – 5.08 (m, 2H), 5.00 – 4.86 (m, 2H), 4.36 – 4.31 (m, 1H), 2.58 (t, *J* = 6.5 Hz, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.2, 147.6, 134.7, 134.3, 133.5, 132.8, 130.9, 130.3, 128.6, 128.4, 125.5, 120.3, 67.4, 56.2, 37.4; IR (neat) v<sub>max</sub> 3328, 1747, 1540, 1355, 1171, 1124 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>18</sub>H<sub>22</sub>N<sub>3</sub>O<sub>6</sub>S: 408.1224, found: 408.1223; [ $\alpha$ ]<sup>22</sup> – 130.9 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.54 (PE/EA = 2/1).


.OBn

#### Compound 7g, 71% yield, d.r.=8:1, colorless oil

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.06 (dd, *J* = 8.8, 1.6 Hz, 1H), 7.59 – 7.55 (m, 1H), 7.49 – 7.46 (m, 2H), 7.36 – 7.31 (m, 3H), 7.25 – 7.22 (m, 2H), 6.02 – 5.99 (m, 0.11H), 5.98 – 5.94 (m, 0.88H), 5.89 – 5.82 (m, 1H), 5.61 – 5.58 (m, 0.11H), 5.56 – 5.52 (m, 0.88H), 5.18 – 5.04 (m, 4H), 4.70 – 4.67 (m, 1H), 4.62 – 4.58 (m, 1H), 3.05 – 2.98 (m, 1H), 2.65 – 2.55 (m, 2H), 2.32 – 2.17 (m, 2 H), 2.11 – 2.05 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.8, 148.3, 136.4, 135.0, 135.0, 134.0, 133.1, 131.5, 131.2, 129.4, 128.5, 128.4, 128.4, 123.8, 118.4, 67.4, 66.1, 60.6, 36.1, 31.6, 30.0; IR (neat) v<sub>max</sub> 2924, 1739, 1542, 1371, 1345, 1161, 1061 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>6</sub>S: 474.1693, found: 474.1687; [α]<sub>0</sub><sup>2</sup> + 8.2 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.63 (PE/EA = 2/1).


#### Substrate for compound **7h**, colorless oil

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.03 – 8.01 (m, 1H), 7.84 – 7.82 (m, 1H), 7.63 – 7.61 (m, 2H), 7.35 – 7.30 (m, 3H), 7.23 – 7.18 (m, 2H), 6.44 (d, *J* = 9.1 Hz, 1H), 5.04 – 4.94 (m, 2H), 4.43 (dt, *J* = 9.5, 4.9 Hz, 1H), 2.88 – 2.74 (m, 2H), 2.05 (t, *J* = 2.6 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  169.1, 155.0, 147.5, 134.6, 133.6, 132.9, 130.2, 128.7, 128.6, 128.4, 125.7, 72.8, 67.9, 55.2, 24.0; IR (neat) v<sub>max</sub> 3292, 2917, 1742, 1538, 1354, 1168, 1114, 739 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>18</sub>H<sub>20</sub>N<sub>3</sub>O<sub>6</sub>S: 382.1067, found: 382.1066; [α]<sub>D</sub><sup>22</sup> - 153.6 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.33 (PE/EA = 2/1).



#### Compound 7h, 85% yield, d.r.=10:1, colorless oil

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.14 – 8.12 (m, 1H), 7.64 – 7.61 (m, 1H), 7.58 – 7.52 (m, 2H), 7.35 – 7.30 (m, 5H), 5.96 (dd, *J* = 6.0, 2.1 Hz ,0.96H), 5.62 (dd, *J* = 5.6, 2.3 Hz, 0.91H), 5.20 – 5.06 (m, 2H), 4.87 - 4.83 (m, 1H), 4.50 (dd, *J* = 8.8, 4.2 Hz, 0.94H), 4.32 (dd, *J* = 8.8, 4.2 Hz, 0.09H), 3.18 - 3.12 (m, 1H), 3.00 - 2.92 (m, 1H), 2.59 - 2.51 (m, 1H), 2.31 - 2.14 (m, 3H), 2.09 (t, *J* = 2.7 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.6, 148.5, 136.6, 134.8, 134.6, 133.3, 131.3, 130.9, 129.4, 128.5, 128.4, 128.4, 124.0, 80.2, 71.8, 67.8, 66.0, 58.5, 31.4, 29.2, 22.1, 14.1; IR (neat) v<sub>max</sub> 3287, 2917, 1740, 1543, 1346, 1167, 742 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for  $C_{23}H_{26}N_3O_6S$ : 472.1537, found: 472.1535;  $[\alpha]_p^{2^2}$  -20.2 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.45 (PE/EA = 2/1)




#### Compound 7i, 77% yield, d.r.>20:1, colorless oil

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.15 – 8.08 (m, 1H), 7.58 – 7.27 (m, 18H), 7.12 - 7.06 (m, 6H), 6.63 (s, 1H), 5.92 (dd, *J* = 5.5, 2.0 Hz, 1H), 5.21 (dd, *J* = 5.5, 2.0 Hz, 1H), 5.17 – 5.02 (m, 2H), 4.98 - 4.96 (m, 1H), 4.60 (t, *J* = 7.0 Hz, 1H), 3.54 (dd, *J* = 14.9, 7.4 Hz, 1H), 3.09 (dd, *J* = 14.9, 7.4 Hz, 1H), 2.42 – 2.36 (m, 1H), 2.20 – 2.07 (m, 2H), 2.00 – 1.99 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.8, 148.7, 142.3, 137.9, 137.2, 135.2, 134.0, 133.2, 131.2, 131.0, 129.7, 128.8, 128.5, 128.2, 128.0, 128.0, 123.7, 120.1, 75.3, 67.4, 65.7, 58.6, 31.1, 31.0, 28.6; IR (neat) v<sub>max</sub> 2926, 1741, 1544, 1372, 1161, 1128 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>43</sub>H<sub>39</sub>N<sub>4</sub>O<sub>6</sub>S: 739.2585, found: 739.2584; [ $\alpha$ ]<sup>2</sup> + 23.0 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.35 (DCM/MeOH = 40/1 with 1/1000 ammonium hydroxide); m.p. = 83-86 °C.

#### Total synthesis of pseudopaline

Compound 13a



To a solution of  $Pd_2(dba)_3$ ·CHCl<sub>3</sub> (63 mg, 0.061 mmol, 0.05 eq) and Trost-ligand *ent*-L2 (144 mg, 0.183 mmol, 0.15 eq) in THF (10.2 mL) was added compound **9** (520 mg, 3.66 mmol, 3 eq) and TEA (370 mg, 3.66 mmol, 3 eq) at 0 °C, then a solution of compound **8** (620 mg, 1.22 mmol, 1 eq) in THF (2 mL) was added into the mixture which was stirred at 0 °C for 2 h. TLC showed **8** was consumed completely. To the mixture at 0 °C was added HF-pyridine (70% solution) (0.63 mL, 4.88 mmol, 4 eq). After stirring for 10h at r.t., the mixture was cooled to 0 °C, diluted with EA (20 mL), quenched with saturated NaHCO<sub>3</sub> (20 mL), and the aqueous phase was extracted with EA (20 mL x 2). The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated *in vacuo* to afford crude product, which was purified by silica gel column chromatography (PE/EA=6/1 to 4/1) to afford compound **13a** (553 mg, 1.15 mmol, 94%) as an oil (d.r.=27:1).

OTBS


TBS-protection of 13a.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.05 (d, J = 1.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.52 – 7.48 (m, 2H), 7.34 – 7.28 (m, 5H), 5.95 – 5.93 (m, 1H), 5.63 – 5.61 (m, 1H), 5.13 (d, J = 12.1 Hz, 1H), 5.05 (d, J = 12.1 Hz, 1H), 4.85 – 4.81 (m, 1H), 4.51 (t, J = 6.7 Hz, 1H), 3.77 – 3.73 (m, 2H), 2.57 – 2.50 (m, 2H), 2.27 – 2.21 (m, 2H), 2.04 – 1.96 (m, 2H), 0.85 (s, 9H), 0.01 (s, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.2, 148.6, 136.2, 135.2, 134.5, 133.2, 131.2, 130.9, 129.8, 128.5, 128.3, 123.8, 67.3, 66.3, 59.9, 55.4, 35.6, 31.3, 28.8, 25.9, 18.2, -5.5, -5.5; IR(neat) v<sub>max</sub> 2928, 2855, 1739, 1544, 1358, 1257, 1161, 1095 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>28</sub>H<sub>42</sub>N<sub>3</sub>O<sub>7</sub>SSi: 592.2507, found: 592.2511; [α]<sub>1</sub><sup>59</sup> – 34.5(c 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.22 (PE/EA = 15/1).

#### Compound 13a

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\bar{o}$  8.04 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.59–7.55 (m, 1H), 7.51 – 7.49 (m, 2H), 7.32 – 7.30 (m, 3H), 7.24 – 7.18 (m, 2H), 5.99 – 5.97 (m, 1H), 5.55 – 5.52 (m, 1H), 5.11 (d, *J* = 12 Hz, 1H), 5.04 (d, *J* = 12 Hz, 1H), 4.87 (dd, *J* = 9.2, 5.2 Hz, 1H), 4.62 – 4.58 (m, 1H), 3.85 – 3.76 (m, 2H), 2.68 – 2.62 (m, 1H), 2.54 – 2.44 (m, 1H), 2.33 – 2.13 (m, 4H), 1.98 – 1.92 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\bar{o}$  171.3, 148.1, 136. 5, 134.8, 134.4, 133.3, 131.2, 129.0, 128.5, 128.4, 123.8, 67.5, 66.37, 58.3, 57.6, 34.0, 31.6, 29.7; IR (neat) v<sub>max</sub> 3557, 2949, 1737, 1543, 1372, 1160, 1061 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>22</sub>H<sub>28</sub>N<sub>3</sub>O<sub>7</sub>S: 478.1642, found: 478.1636; [ $\alpha$ ]<sup>24</sup> 1.5 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.22 (PE/EA = 2/1).


#### Compound 5a



The Ph<sub>2</sub>P-Py (264 mg, 1.00 mmol, 1.5 eq) was dissolved in THF (3 mL) and to this solution was added DEAD (158  $\mu$ L, 1.00 mmol, 1.5 eq) at 0 °C under argon. The mixture was stirred for 10 minutes, then a solution of compound **6** (265 mg, 0.47 mmol, 0.7 eq) in THF (1 mL) was added. A solution of compound **13a** (310 mg, 0.67 mmol, 1 eq) in THF (2.7 mL) was dropwise into the solution. After stirring at r.t. for 2 h, the mixture was evaporated under *in vacuo*, and the residue was dissolved in EA and washed by 2N HCl (5 x 10 mL) and brine. The organic phase was concentrated *in vacuo*. The residue was purified by silica gel column chromatography (PE/EA = 7/1) to afford the desired product (389 mg, 0.39 mmol, 82%) as a colorless oil.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.06 – 7.99 (m, 1H), 7.97 (d, *J* = 0.9 Hz, 1H), 7.87 (dd, *J* = 7.9, 1.1 Hz, 1H), 7.62 – 7.54 (m, 1H), 7.53 – 7.26 (m, 18H), 7.22 – 7.12 (m, 2H), 5.96 (dd, *J* = 5.5, 2.1 Hz, 1H), 5.55 (dd, *J* = 5.5, 2.1 Hz, 1H), 5.38 (s, 2H), 5.16 – 4.86 (m, 5H), 4.70 – 4.66 (m, 1H), 4.36 (t, *J* = 6.5 Hz, 1H), 3.79 – 3.58 (m, 1H), 3.53 – 3.39 (m, 1H), 3.34 (dd, *J* = 15.6, 5.1 Hz, 1H), 3.12 (dd, *J* = 15.6, 9.6 Hz, 1H), 2.60 – 2.56 (m, 2H), 2.31 – 2.16 (m, 3H), 2.00 – 1.90 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.7, 169.9, 148. 5, 148.4, 148.0, 138.9, 136.8, 136. 7, 135.0, 134.8, 134.4, 134.1, 133.4, 133.3, 132.2, 131.4, 131.4, 131.2, 130.0, 129.4, 129.1, 128.8, 128.6, 128.5, 128.5, 128.5, 128.4, 123.9, 123.7, 115.0, 77.4, 77.1, 76.7, 69.8, 67.7, 67.5, 66.3, 60.3, 57.8, 45.3, 33.6, 31.6, 29.6, 29.2; IR (neat) v<sub>max</sub> 2955, 1739, 1542, 1213, 1162, 970, 730, 580 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>49</sub>H<sub>47</sub>N<sub>6</sub>O<sub>14</sub>S<sub>2</sub>: 1007.2586, found: 1007.2585; [ $\alpha$ ]<sup>5</sup><sub>2</sub>-17.2 (c 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.29 (PE/EA = 1/1).

#### Compound 14a



Compound **5a** (380 mg, 0.377 mmol, 1 eq) was dissolved in dioxane (25.1 mL) and H<sub>2</sub>O (12.6 mL), and to this solution was added 2,6– lutidine (174  $\mu$ L, 1.51 mmol, 4 eq), OsO<sub>4</sub> (0.01 M in *t*-BuOH) (7.6 mL, 0.076 mmol, 0.2 eq) and NaIO<sub>4</sub> (808 mg, 3.77 mmol, 10 eq) at r.t.. After stirring for 3 h at r.t., the resulting solution was quenched by saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (12 ml) and extracted by EA (16 mL x 3) and the combined organic extracts were washed with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (20 mL x 2), 5% NaH<sub>2</sub>PO<sub>4</sub> solution (20 mL x 2) and brine. The organic phases were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and the filtrate was concentrated *in vacuo*. The residue was directly used in next step without further purification. The residue was dissolved in acetone (18.9 mL), then Jones reagent (2 M, 414  $\mu$ L, 0.829 mmol, 2.2 eq) was added to the solution at 0 °C. After stirring for 16 h at r.t., the reaction mixture was quenched by *i*-PrOH (1 mL), diluted with EA (20 mL) and washed with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (10 mL x 2) and brine (10 mL). The water phase was extracted by EA (5 mL x 2). The combined organic phases were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and the filtrate was concentrated *in vacuo*. The residue was purified by silica gel column chromatography (DCM/MeOH = 100:1 with 1/10000 AcOH) to afford pure product **14a** (235 mg, 0.219 mmol, 58%) as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.35 (br, 2H), 8.42 (s, 1H), 7.97 (d, J = 7.2 Hz, 1H), 7.86 (d, J = 7.2 Hz, 1H), 7.65 – 7.01 (m, 23H), 5.47 – 5.28 (m, 2H), 5.13 – 4.63 (m, 6H), 4.47 (m, 1H), 3.89 – 3.65 (m, 1H), 3.49 – 3.38 (m, 2H), 3.14 (dd, J = 16.0, 9.6 Hz, 1H), 2.67 – 2.25 (m, 4H), 2.16 – 2.08 (m, 1H), 1.98 – 1.86 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  177.0, 173.0, 171.9, 169.1, 147.9, 147.8, 147.3, 136.7, 135.4, 134.5, 134.4, 133.8, 133.4, 132.7, 131.9, 131.8, 131.7, 131.6, 131.1, 129.2, 128.9, 128.9, 128.8, 128.6, 128.5, 123.9, 123.8, 116.2, 77.4, 77.3, 77.1, 76.8, 70.9, 68.1, 67.9, 60.1, 58.2, 56.8, 45.2, 31.3, 28.1, 16.3; IR (neat) v<sub>max</sub> 3148, 2961, 1739, 1544, 1372, 1165, 753, 591 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>49</sub>H<sub>47</sub>N<sub>6</sub>O<sub>18</sub>S<sub>2</sub>: 1071.2384, found: 1071.2585; [ $\alpha$ ]<sub>p</sub><sup>19</sup> +76.3 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.59 (DCM/MeOH = 10/1 with 1/10000 AcOH); m.p. = 102-105 °C.

Pseudopaline 2




To a solution of diacid **14a** (184 mg, 0.172 mmol, 1 eq) in DCM (17.2 mL) was added anisole (206  $\mu$ L, 1.89 mmol, 11 eq) and trifluoromethanesulfonic acid (151  $\mu$ L, 1.72 mmol, 10 eq) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h, then warmed to room temperature, and stirred for 1.5 h. The reaction was quenched with a solution of NaHCO<sub>3</sub> (218 mg, 2.58 mmol, 15 eq) in water (20 mL) at 0 °C and stirred for an additional 0.5 h. The mixture was washed with DCM (20 mL x 3) and the water phase was concentrated *in vacuo* and directly used for the next step without further purification. The crude mixture and K<sub>2</sub>CO<sub>3</sub> (190 mg, 1.37 mmol, 8 eq) were dissolved in dry DMF (8.6 mL) and to this solution was added thiophenol (352  $\mu$ L, 3.44 mmol, 20 eq). After stirring for 14 h at r.t. water (20 mL) was added and the aqueous phase was washed with DCM (20 mL x 3). Then the aqueous phase was concentrated *in vacuo* to the resulting solid which was purified by gel column to afford **2** (49 mg, 0.127 mmol, 74 %) as a white solid. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O)  $\delta$  7.72 (d, *J* = 0.9 Hz, 1H), 6.92 (s, 1H), 3.61 (t, *J* = 6.3 Hz, 1H), 3.32 – 3.19 (m, 2H), 3.10 (dt, *J* = 11.2, 5.4 Hz, 1H), 3.03 (d, *J* = 6.4 Hz, 2H), 2.90 (ddd, *J* = 12.4, 8.9, 5.8 Hz, 1H), 2.20 (t, *J* = 7.9 Hz, 2H), 2.03 – 1.78 (m, 4H); <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O)  $\delta$  181.8, 176.9, 176.1, 175.5, 135.6, 131.3, 117.4, 62.9, 62.8, 62.2, 45.6, 33.8, 28.6, 28.4, 28.1; IR (neat) v<sub>max</sub> 3359, 1570, 1395, 1103, 995, 831cm<sup>-1</sup>; HRMS (ESI): [M-H]<sup>-</sup> calculated for C<sub>15</sub>H<sub>21</sub>N<sub>4</sub>O<sub>8</sub> : 385.1365, found: 385.1372; ( $\alpha_{19}^{19} + 5.9$  (*c* 1, H<sub>2</sub>O); m.p.>330°C.

#### Total synthesis of epi-pseudopaline

Same procedure as the synthesis of pseudopaline.


Compound 7b, colorless oil, 27:1 d.r.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.05 (d, *J* = 8.0 Hz, 1H), 7.60 – 7.57 (m, 1H), 7.54 – 7.45 (m, 2H), 7.35 – 7.29 (m, 5H), 5.97 (dd, *J* = 5.2, 2.0 Hz, 1H), 5.60 (dd, *J* = 5.2, 2.0 Hz, 1H), 5.14 (d, *J* = 12.2 Hz, 1H), 5.08 (d, *J* = 12.2 Hz, 1H), 5.04 – 5.00 (m, 1H), 4.36 (dd, *J* = 8.0, 4.2 Hz, 1H), 3.71 (dd, *J* = 8.0, 4.0 Hz, 2H), 2.56 – 2.31 (m, 2H), 2.32 – 2.14 (m, 2H), 2.10 – 1.84 (m, 2H), 0.85 (s, 9H), -0.01 (d, *J* = 4.0 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  171.0, 148.6, 137.2, 135.1, 134.1, 133.3, 131.3, 130.7, 128.8, 128.5, 128.4, 128.3, 123.9, 67.4, 65.8, 60.0, 54.5, 35.2, 31.1, 28.8, 25.9, 18.2, -5.4, -5.6; IR (neat) v<sub>max</sub> 2958, 2928, 2856, 1740, 1544, 1360, 1259, 1091 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]+ calculated for C<sub>28</sub>H<sub>42</sub>N<sub>3</sub>O<sub>7</sub>SSi: 592.2507, found: 592.2515; [α]<sub>2</sub><sup>24</sup> – 35.8 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.22 (PE/EA = 15/1).




Compound 13b, 87% yield, colorless oil, d.r.=27:1

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.05 (d, *J* = 8.0 Hz, 1H), 7.58 – 7.53 (m, 1H), 7.48 (d, *J* = 8.2 Hz, 2H), 7.33 (m, 3H), 7.25–7.23 (m, 2H), 5.99 (dd, *J* = 5.6, 2.4 Hz, 1H), 5.56 (dd, *J* = 5.6, 2.4 Hz, 1H), 5.13 – 4.97 (m, 3H), 4.50 (t, *J* = 6.8 Hz, 1H), 3.80 – 3.72 (m, 2H), 2.54 – 2.48 (m, 2H), 2.32 – 2.27 (m, 2H), 2.00 – 1.97 (m, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  171.3, 148.4, 137.5, 134.7, 133.7, 133.4, 131.4, 130.7, 128.6, 128.6, 128.5, 128.45, 123.9, 67.7, 65.5, 59.2, 55.6, 34.4, 31.1, 29.5; IR (neat) v<sub>max</sub> 3559, 2961, 2924, 1738, 1542, 1373, 1256, 1158 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>22</sub>H<sub>28</sub>N<sub>3</sub>O<sub>7</sub>S: 478.1642 , found: 478.1648; [ $\alpha$ ]<sup>22</sup><sub>D</sub> –31.7 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.22 (PE/EA = 2/1).




#### Compound 5b, 80% yield, colorless oil

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.06 – 7.98 (m, 2H), 7.91 – 7.87 (m, 1H), 7.60 – 7.26 (m, 20H), 7.22 – 7.12 (m, 2H), 5.96 (dd, *J* = 5.5, 2.1 Hz, 1H), 5.55 (dd, *J* = 5.5, 2.1 Hz, 1H), 5.38 (s, 2H), 5.16 – 5.03 (m, 3H), 4.97 – 4.90 (m, 3H), 4.10 (d, *J* = 8.0 Hz, 1H), 3.79 – 3.58 (m, 1H), 3.44 – 3.37 (m, 1H), 3.34 (dd, *J* = 15.6, 5.1 Hz, 1H), 3.12 (dd, *J* = 15.6, 9.6 Hz, 1H), 2.59 – 2.49 (m, 1H), 2.45 – 2.35 (m, 1H), 2.26 – 2.10 (m, 3H), 2.00 – 1.90 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.7, 169.8, 148.4, 148.3, 147.8, 138. 9, 138.1, 136.7, 134.8, 134. 8, 134.0, 133.8, 133.4, 133.4, 132.1, 131.6, 131.3, 131.0, 130.7, 129.0, 128.8, 128.7, 128.5, 128.5, 128.4, 128.4, 128.4, 128.3, 128.2, 124.0, 123.6, 114.9, 69.7, 67.7, 67.3, 65.3, 60.2, 55.8, 45.1, 33.7, 31.2, 29.4, 28.6; IR (neat) v<sub>max</sub> 2958, 1742, 1543, 1405, 1372, 1244, 1163 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>49</sub>H<sub>47</sub>N<sub>6</sub>O<sub>14</sub>S<sub>2</sub>: 1007.2586, found: 1007.2587; [α]<sub>D</sub><sup>19</sup>–23.7 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.29 (PE/EA = 1/1).



#### Compound 14b, 55% yield for 2 steps, white solid

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.42 (s, 2H contain COOH), 7.97 (d, *J* = 7.2 Hz, 1H), 7.86 (d, *J* = 7.2 Hz, 1H), 7.55 – 7.29 (m, 18H), 7.25 – 7.22 (m, 3H), 7.17 – 7.13 (m, 2H), 5.38 (s, 2H), 5.18 – 5.08 (m, 2H), 4.94 (s, 2H), 4.89 (t, *J* = 6 Hz, 1H), 4.50 – 4.46 (m, 1H), 4.29 – 4.25 (m, 1H), 3.65 – 3.59 (m, 1H), 3.56 – 3.49 (m, 1H), 3.44 (dd, *J* = 8.4, 4.2 Hz, 1H), 3.11 (dd, *J* = 8.4, 4.2 Hz, 1H), 2.67 – 2.62 (m, 1H), 2.51 – 2.40 (m, 2H), 2.35 – 2.28 (m, 2H), 2.11 – 2.04 (m, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  176.7, 172.6, 170.0, 169.6, 148.7, 147.8, 147.5, 137.0, 136.5, 134.8, 134.7, 134.0, 133.6, 133.5, 132.7, 132.2, 131.7, 131.2, 130.9, 129.4, 129.0, 128.9, 128.8, 128.7, 128.6, 128.6, 128.6, 128.6, 128.5, 128.4, 128.4, 128.3, 127.7, 127.0, 123.8, 123.8, 115.8, 70.6, 69.7, 68.1, 67.6, 60.5, 59.4, 57.8, 32.3, 30.4, 28.3, 25.6; IR (neat) v<sub>max</sub> 2923, 1737, 1543, 1372, 1259, 1017 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>49</sub>H<sub>47</sub>N<sub>6</sub>O<sub>18</sub>S<sub>2</sub> : 1071.2383, found: 1071.2396; [a]<sup>51</sup><sub>2</sub> – 2.5 (c 0.8, CHCl<sub>3</sub>); Rf =0.47 (DCM/ACOH = 20/1); m.p. = 89-91°C.



epi-pseudopaline 3, 80% yield for 2 steps, white solid.

<sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 7.70 (s, 1H), 6.96 (s, 1H), 3.68 (t, *J* = 7.2 Hz, 1H), 3.43 (t, *J* = 7.2 Hz, 1H), 3.32 (t, *J* = 7.2 Hz, 1H), 3.07 (m, 2H), 2.99 (m, 2H), 2.25 (t, *J* = 7.2 Hz, 2H), 2.00 (m, , 2H), 1.89 (q, *J* = 7.2 Hz, 2H); <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 181.8, 175.7, 174.9, 174.8, 135.9, 131.7, 117.1, 62.3, 61.5, 59.9, 44.3, 33.7, 27.7, 27.0, 26.3; IR (neat)  $v_{max}$  3395, 1628, 1574, 1399, 1318, 1118, 835, 758cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>15</sub>H<sub>23</sub>N<sub>4</sub>O<sub>8</sub>: 387.1510 , found: 387.1511; [α]<sub>2</sub><sup>21</sup>+9.5 (*c* 0.9, H<sub>2</sub>O); m.p. >330 °C.

#### Synthesis of Fmoc-pseudopaline 17




Scheme S2: Synthesis of the Fmoc-pseudopaline

To a solution of pseudopaline (4 mg, 0.0104 mmol, 1 eq) in water (0.6 mL) and pH=10 buffer (0.4 mL) was added a solution of Fmoc– NHS (17 mg, 0.052 mmol, 5 eq) in ACN (0.6 mL) at room temperature. After stirring for 3h at r.t., the reaction mixture was subjected directly to C–18 reverse phase column (a gradient of 0% – 50% acetonitrile in water) to afford the crude product which was purified further by reverse phase prep-TLC with 30% acetonitrile in water to give pure Fmoc-pseudopaline (2.1 mg, 3.4 µmol, 33%). This compound is unstable in water for a long period of time, so the NMR spectrum was recorded immediately.

<sup>1</sup>H NMR (400 MHz,  $D_2O$ )  $\delta$  7.92 (t, J = 7.2, 3H), 7.72 (d, J = 7.2, 2H), 7.48 (t, J = 7.2, 3H), 7.42 (t, J = 7.2, 3H), 7.20 (s,1H), 4.92 (d, J = 5.2, 2H), 4.49 (t, J = 5.2, 1H), 3.89 (t, J = 5.6, 1H), 3.65 – 3.59 (m, 2H), 3.24 (t, J = 7.2, 2H), 3.09 (d, J = 5.2, 2H), 2.38 (t, J = 7.2, 2H), 2.30 – 2.21(m, 2H), 2.10 – 2.08(m, 2H); <sup>13</sup>C NMR (201 MHz,  $D_2O$ )  $\delta$  180.3, 173.2, 172.2, 172.0, 149.0, 143.1, 141.0, 138.0, 136.2, 128.2, 127.5, 125.0, 120.2, 115.6, 69.4, 62.8, 61.6, 59.8, 46.4, 43.5, 32.8, 27.4, 26.8, 26.5; IR (neat) v<sub>max</sub> 3397, 1767, 1700, 1616, 1532, 1491, 1449, 1410, 1281, 1248, 1215,1169, 1107, 1104, 763, 740 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>30</sub>H<sub>33</sub>N<sub>4</sub>O<sub>10</sub>: 609.2191, found: 609.2193; [M-H]<sup>-</sup> calculated for C<sub>30</sub>H<sub>31</sub>N<sub>4</sub>O<sub>10</sub>: 607.2046, found: 607.2046; [ $\alpha$ ]<sup>20</sup> +18 (*c* 0.1, H<sub>2</sub>O);  $R_f$  = 0.3 (ACN/H<sub>2</sub>O = 3:7).

#### Natural product isolation




Scheme S4. Comparison of the natural Fmoc-pseudopaline and synthetic Fmoc-pseudopaline.

The bacteria cells were separated from the broth by centrifugation and filtration. The filtrate (4.2 L) was evaporated under reduced pressure to afford a crude mixture (69.54 g) then washed by  $CH_2Cl_2$ . The residue (68.10 g) was applied on a Diation<sup>®</sup> HP-20 column eluting with  $H_2O$  (1 L), 10% MeOH (1 L), 25% MeOH (1 L), 60% MeOH (1 L), and 100% MeOH (1 L) to yield five fractions (A-E). 50  $\mu$ L

of each fraction was added to 50  $\mu$ L of borate buffer (0.2 M, pH 10.0) and 100  $\mu$ L of Fmoc-NHS (100 mM in acetonitrile), and stirred at room temperature overnight, followed by addition of 200  $\mu$ L MeOH then subjected to LC–MS analysis.


Fraction A (65.35 g), where Fmoc-pseudopaline derivative was previously detected by LC-MS after modification of Fmoc, was eluted through Sephadex<sup>®</sup> LH-20 column with 100% H<sub>2</sub>O and yielded three sub-fractions, A1-A3. 50  $\mu$ L of each sub-fraction was added to 50  $\mu$ L of borate buffer (0.2 M, pH 10.0) and 100  $\mu$ L of Fmoc-NHS (100 mM in acetonitrile), and stirred at room temperature overnight, followed by addition of 200  $\mu$ L MeOH then subjected to LC–MS analysis by which Fmoc-pseudopaline was found from sub-fraction A1.

Sub-fraction A1 (220.1 mg) was added to Fmoc-NHS in acetonitrile. After stirring for overnight, the mixture was subjected to C-18 reverse phase column with an isocratic conditions of 50% acetonitrile in water giving three sub-fractions (A1a-A1c). Sub-fraction A1b (22.6 mg) was further purified by C-18 reverse phase column with a gradient of 0%-50% acetonitrile in water followed by reverse phase prep. TLC with 30% acetonitrile in water to afford Fmoc-pseudopaline (1.1 mg).



Scheme S5: (e) **18a-c** (1.2 eq), Ph<sub>3</sub>P (1.5 eq), DEAD (1.5 eq), THF (0.1 M), 0°C-r.t., 2 h; 76% for **19a**, 78% for **19b**, 96% for **19c**; (f) OsO<sub>4</sub> (0.2 eq), NalO<sub>4</sub> (10 eq), dioxane/H<sub>2</sub>O (2:1, 0.01 M) 2,6-lutidine (4 eq), r.t., 3 h; (g) Jones reagent (2.2 eq), acetone (0.02 M), 0°C-r.t., 16 h; 65% for **20a**, 2 steps, 67% for **20b**, 2 steps, 54% for **20c**, 2 steps; (h) TfOH (5 eq), anisole (15 eq), DCM (0.01 M), 0°C, 0.5 h; r.t., 2 h for **20a**; TfOH (10 eq), anisole (15 eq), DCM (0.01 M), 0°C, 0.5 h; r.t., 2 h for **20a**; TfOH (10 eq), anisole (15 eq), DCM (0.01 M), 0°C, 0.5 h; r.t., 1.5 h for **20c**; (i) PhSH (20 eq), K<sub>2</sub>CO<sub>3</sub> (8 eq), DMF (0.02 M), r.t., 14 h; 75% for **15a**, 2 steps, 72% for **15b**, 2 steps, 78% for **15c**, 2 steps.


Compound 19a



The PPh<sub>3</sub> (86 mg, 0.33 mmol, 1.5 eq) was dissolved in THF (1 mL) and to this solution was added DEAD (52  $\mu$ L, 0.33 mmol, 1.5 eq) at 0 °C under argon. The mixture was stirred for 10 minutes, then a solution of compound **18a** (95 mg, 0.26 mmol, 1.2 eq) in THF (0.7 mL) was added. A solution of compound **13a** (100 mg, 0.22 mmol, 1.0 eq) in THF (0.5 mL) was added dropwise into the solution. After stirring at r.t. for 2 h, the mixture was evaporated *in vacuo*, and the residue was purified by silica gel column chromatography (DCM/EA = 10/1) to afford the desired product (134 mg, 0.167 mmol, 76%) as a colorless oil.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.05 (dd, *J* = 8.3, 1.4 Hz, 1H), 7.92 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.65 – 7.35 (m, 6H), 7.35 – 7.30 (m, 6H), 7.28 – 7.24 (m, 2H), 7.23 – 7.17 (m, 2H), 6.00 (dd, *J* = 5.6, 2.3 Hz, 1H), 5.57 (dd, *J* = 5.6, 2.3 Hz, 1H), 5.13 (d, *J* = 12.1 Hz, 1H), 5.04 (d, *J* = 12.1 Hz, 1H), 5.00 (d, *J* = 12.2 Hz, 1H), 4.91 (d, *J* = 12.2 Hz, 1H), 4.84 (q, *J* = 7.3 Hz, 1H), 4.68 (d, *J* = 8.5 Hz, 1H), 4.43 (t, *J* = 6.7 Hz, 1H), 3.70 (ddd, *J* = 16.1, 10.9, 5.6 Hz, 1H), 3.37 (ddd, *J* = 15.6, 11.2, 4.5 Hz, 1H), 2.67 – 2.53 (m, 2H), 2.36 – 2.20 (m, 3H), 2.02 (ddd, *J* = 14.4, 7.2, 3.6 Hz, 1H), 1.57 (d, *J* = 7.4 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  171.0, 170.7, 148.6, 148.0, 136.9, 135.1, 135.0, 134.6, 133.6, 133.5, 132.6, 131.7, 131.5, 131.4, 131.0, 129.5, 128.8, 128.7, 128.7, 128.5, 124.1, 124.0, 67.9, 67.5, 66.5, 58.0, 56.6, 45.0, 34.3, 31.7, 29.5, 17.3; IR (neat) v<sub>max</sub> 1741, 1544, 1556, 1373, 1159, 1061 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>38</sub>H<sub>42</sub>N<sub>5</sub>O<sub>12</sub>S<sub>2</sub>: 824.2266, found: 824.2263; [α]<sub>2</sub><sup>2+</sup> - 21.2 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.30 (PE/EA = 2/1).

Compound 20a



Compound **19a** (120 mg, 0.15 mmol, 1 eq) was dissolved in dioxane (10 mL) and H<sub>2</sub>O (5 mL), and to this solution was added 2,6– lutidine (69  $\mu$ L, 0.59 mmol, 4 eq), OsO<sub>4</sub> (0.01M in *t*-BuOH) (3.0 mL, 0.03 mmol, 0.2 eq) and NalO<sub>4</sub> (317 mg, 1.48 mmol, 10 eq) at r.t.. After stirring for 3 h at r.t., the resulting solution was quenched by saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (12 mL) and extracted by EA (10 mL x 3) and the combined organic extracts were washed with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (15 mL x 2), 5% NaH<sub>2</sub>PO<sub>4</sub> solution (15 mL x 2) and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and the filtrate was concentrated *in vacuo*. The residue was directly used in next step without further purification. The residue was dissolved in acetone (7.5 mL) and Jones reagent (2 M, 163  $\mu$ L, 0.33 mmol, 2.2 eq) was added to the solution at 0 °C and the mixture was allowed to stir for 16 h at r.t. before quenched by *i*-PrOH (1 mL). The mixture was diluted by EA (20 mL) and washed by saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (10 mL x 2) and brine (10 mL), the water phase was extracted by EA (5 mL). The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> the filtrate was concentrated *in vacuo*. The residue was purified by silica gel column chromatography to afford pure product **20a** (85 mg, 0.097 mmol, 65%) as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.10 (d, *J* = 7.6 Hz, 1H), 7.93 (d, *J* = 7.6, 1H), 7.60 – 7.46 (m, 5H), 7.42 – 7.39 (m, 1H), 7.32 – 7.28 (m, 6H), 7.25 – 7.22 (m, 2H), 7.20 – 7.16 (m, 2H), 5.11 (d, *J* = 12.1 Hz, 1H), 5.03 (d, *J* = 12.1 Hz, 1H), 4.96 (d, *J* = 12.2 Hz, 1H), 4.88 (d, *J* = 12.2 Hz, 1H), 4.81 (q, *J* = 7.5 Hz, 1H), 4.74 (t, *J* = 6.5 Hz, 1H), 4.41 (dd, *J* = 8.9, 4.5 Hz, 1H), 3.77 – 3.65 (m, 1H), 3.39 – 3.25 (m, 1H), 2.64 – 2.35 (m, 5H), 2.11 – 1.98 (m, 1H), 1.51 (d, *J* = 7.4 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  177.6, 172.5, 171.8, 171.1, 148.2, 147.9, 135.1, 134.4, 134.4, 133.8, 132.5, 132.3, 132.2, 132.0, 131.8, 131.1, 129.1, 128.9, 128.9, 128.8, 128.7, 128.6, 128.5, 128.5, 128.4, 128.4, 124.3, 124.0, 68.7, 67.5, 58.8, 58.1, 56.7, 44.7, 33.0, 31.0, 26.3, 17.2; IR (neat) v<sub>max</sub> 1740, 1544, 1372, 1153, 750, 587 cm<sup>-1</sup>; HRMS (ESI): [M+NH<sub>4</sub>]<sup>+</sup> calculated for C<sub>38</sub>H<sub>42</sub>N<sub>5</sub>O<sub>16</sub>S<sub>2</sub> : 888.2062, found: 888.2048; [a]<sub>0</sub><sup>22</sup> – 26.2 (*c* 1.9, CHCl<sub>3</sub>); R<sub>f</sub> = 0.45 (DCM/MeOH = 10/1); m.p. = 125-128 °C.

Compound 15a




To a solution of diacid **20a** (40 mg, 0.046 mmol, 1 eq) in DCM (4.6 mL) was added anisole (75  $\mu$ L, 0.690 mmol, 15 eq) and trifluoromethanesulfonic acid (20  $\mu$ L, 0.23 mmol, 5 eq) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h, then warmed to room temperature, and stirred for 2 h. The reaction was quenched with a solution of NaHCO<sub>3</sub> (31 mg, 0.370 mmol, 8 eq) in water (5 mL) at 0 °C and stirred for an additional 0.5 h. The mixture was washed with DCM (10 mL x 3) and the water phase was concentrated *in vacuo* and directly used for the next step without further purification. The crude mixture and K<sub>2</sub>CO<sub>3</sub> (51 mg, 0.370 mmol, 8 eq) were dissolved in dry DMF (2.3 mL) and to this solution was added thiophenol (94  $\mu$ L, 0.920 mmol, 20 eq). The reaction mixture was stirred for 14 h at room temperature before water (10 mL) was added and washed with DCM (10 mL x 3). Then the aqueous phase was concentrated *in vacuo*. The resulting solid was purified by gel column to afford **15a** (11 mg, 0.034 mmol, 75 %) as a white solid.

<sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 3.68 (m, 2H), 3.60 (t, *J* = 5.9 Hz, 1H), 3.24 (t, *J* = 7.7 Hz, 2H), 2.41 (t, *J* = 7.3 Hz, 2H), 2.29 (m, 2H), 2.11 (m, 2H), 1.49 (d, *J* = 7.2 Hz, 3H);

<sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 181.2, 174.7, 173.5, 172.2, 63.0, 59.9, 57.9, 42.6, 33.6, 27.0, 26.8, 14.9; IR (neat)  $v_{max}$  3383, 3038, 1514, 1399, 1117 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>12</sub>H<sub>21</sub>N<sub>2</sub>O<sub>8</sub>: 321.1292, found: 321.1293; [α]<sub>p</sub><sup>22</sup> + 10.7 (*c* 1, H<sub>2</sub>O); m.p.>330°C.


#### Compound 18b



To a mixture of compound **S-1** (2 g, 7.14 mmol, 1 eq) in THF (20 mL) and H<sub>2</sub>O (20 mL) was added NaHCO<sub>3</sub> (2.4 g, 28.60 mmol, 4 eq) and NsCl (1.6 g, 7.14 mmol, 1 eq) at r.t. After stirring for overnight, the mixture was diluted with EA (100 mL), and adjusted to pH~3 with 1N HCl. The organic phase was washed with 1N HCl (20 mL x 2), brine (20 mL x 2), dried with Na<sub>2</sub>SO<sub>4</sub>, and evaporated *in vacuo*. The residue was used in next step without purification. To the residue in DMF (20 mL) was added NaHCO<sub>3</sub> (0.90 g, 10.71 mmol, 1.5 eq) and BnBr (0.85 mL, 7.14 mmol, 1 eq), the mixture was stirred for 12 h at room temperature. The mixture was quenched with water (20 mL), and extracted with Et<sub>2</sub>O (100 mL x 1). The organic phase was washed with H<sub>2</sub>O (20 mL x 4), brine (20 mL x 1), dried with Na<sub>2</sub>SO<sub>4</sub>, and evaporated under *in vacuo*. The residue was further purified by silica gel column chromatography (PE/EA = 10/1) to afford the desired product (990 mg, 1.79 mmol, 25%) as yellow oil.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.98 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.79 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.65 – 7.55 (m, 2H), 7.39 – 7.28 (m, 8H), 7.16 (dd, *J* = 6.5, 3.0 Hz, 2H), 6.18 (d, *J* = 9.0 Hz, 1H), 5.10 (s, 2H), 4.91 (d, *J* = 12.4 Hz, 1H), 4.87 (d, *J* = 12.4 Hz, 1H), 4.77 (d, *J* = 6.2 Hz, 1H), 4.20 (td, *J* = 8.6, 4.9 Hz, 1H), 3.14 (q, *J* = 6.6 Hz, 2H), 1.91 – 1.82 (m, 1H), 1.81 – 1.69 (m, 1H), 1.5 – 1.34 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.9, 156.6, 147.7, 136.7, 134.8, 134.1, 133.7, 132.9, 130.4, 128.76, 128. 73, 128.6, 128.5, 128.23, 128.19, 125.7, 67.5, 66.8, 56.7, 40.6, 32.8, 29.3, 22.2; IR (neat) v<sub>max</sub> 1719, 1541, 1455, 1355, 1260, 1170, 1124 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>30</sub>N<sub>3</sub>O<sub>8</sub>S: 556.1748, found: 556.1744; [d]<sub>2<sup>1</sup></sub> – 90.3 (*c* 2.7, CHCl<sub>3</sub>); R<sub>f</sub> = 0.30 (PE/EA = 5/3).


#### Compound 19b



PPh<sub>3</sub> (170 mg, 0.65 mmol, 1.5 eq) was dissolved in THF (2 mL) and to this solution was added DEAD (100  $\mu$ L, 0.65 mmol, 1.5 eq) at 0 °C under argon. The mixture was stirred for 10 minutes, then a solution of **18b** (290 mg, 0.52 mmol, 1.2 eq) in THF (2 mL) was added. A solution of **13a** (200 mg, 0.43 mmol, 1.0 eq) in THF (1 mL) was added into the solution. After stirring for 2 h, the mixture was evaporated *in vacuo*, and the residue was purified by silica gel column chromatography (DCM/EA = 15/1) to afford the desired product (404 mg, 0.41 mmol, 78%) as colorless oil.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.04 (dd, *J* = 8.2, 1.5 Hz, 1H), 7.89 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.55 – 7.46 (m, 3H), 7.45 – 7.28 (m, 13H), 7.17 (dd, *J* = 6.6, 3.0 Hz, 2H), 6.01 (dd, *J* = 5.8, 2.3 Hz, 1H), 5.58 (dd, *J* = 5.8, 2.3 Hz, 1H), 5.15 – 4.94 (m, 5H), 4.87 – 4.83 (m, 2H), 4.74 – 4.68 (m, 1H), 4.62 (dd, *J* = 10.4, 4.5 Hz, 1H), 4.38 (t, *J* = 6.8 Hz, 1H), 3.75 – 3.62 (m, 1H), 3.43 – 3.27 (m, 1H), 3.18 – 3.10 (m, 1H), 2.66 – 2.60 (m, 1H), 2.52 – 2.46 (m, 1H), 2.39 – 2.32 (m, 3H), 2.10 – 2.00 (m, 2H), 1.80 – 1.70 (m, 1H), 1.53 – 1.41 (m, 4H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  168.0, 167.8, 153.9, 145.9, 145.4, 134.2, 132.3, 132.0, 130.9, 130.8, 129.6, 128.9, 128.8, 128.7, 128.3, 126.9, 126.09, 126.07, 126.0, 125.96, 125.94, 125.9, 125.5, 125.4, 121.4, 121.2, 65.3, 64.8, 64.0, 63.9, 58.5, 42.7, 38.2, 31.3, 29.1, 27.3, 27.2, 26.9, 26.5, 20.8; IR (neat) v<sub>max</sub> 2925, 1739, 1545, 1456, 1374, 1166 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>49</sub>H<sub>52</sub>N<sub>5</sub>O<sub>14</sub>S<sub>2</sub>: 998.2947, found: 998.2934; [ $\alpha$ ]<sup>21</sup><sub>2</sub> – 6.2 (*c* 0.3, CHCl<sub>3</sub>); R<sub>f</sub> = 0.35 (PE/EA = 5/3).


#### Compound 20b



Compound **19b** (281 mg, 0.28 mmol, 1 eq) was dissolved in dioxane (18.6 mL) and H<sub>2</sub>O (9.3 mL). To this solution was added 2,6– lutidine (130  $\mu$ L, 1.12 mmol, 4 eq), OsO<sub>4</sub> (0.01M in *t*-BuOH) (5.6 mL, 0.056 mmol, 0.2 eq) and NaIO<sub>4</sub> (600 mg, 2.81 mmol, 10 eq) at r.t.. After stirring for 2 h at r.t., the resulting solution was quenched by saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (20 mL) and extracted by EA (20 mL x 3) and the combined organic extracts were washed with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (15 mL x 2), 5% NaH<sub>2</sub>PO<sub>4</sub> solution (15 mL x 2) and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and the filtrate was concentrated *in vacuo*. The residue was directly used in next step without further purification. The residue was dissolved in acetone (14 mL) and Jones reagent (2 M, 309  $\mu$ L, 0.62 mmol, 2.2 eq) was added to the solution at 0 °C and the mixture was allowed to stir for 2 h at r.t. before quenched by *i*-PrOH (1 mL). The mixture was diluted by EA (20 mL) and washed by saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (10 mL x 2) and brine (10 mL). The aqueous phase was extracted by EA (5 mL). The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> the filtrate was concentrated *in vacuo*. The residue was purified by silica gel column chromatography to afford pure product **20b** (199 mg, 0.19 mmol, 67%) as white solid. Single crystals with X-ray diffraction quality were grown by dissolving the material in CDCl<sub>3</sub>. The mixture was lightly capped and the solvents were allowed to slowly evaporate.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.20 – 8.12 (m, 1H), 8.10 – 8.05 (m, 1H), 7.75 – 7.48 (m, 5H), 7.42 – 7.21 (m, 16H), 7.20 – 7.12 (m, 2H), 6.89 – 6.84 (m, 1H), 5.34 – 4.75 (m, 8H), 4.70 – 4.60 (m, 1H), 4.49 (dd, *J* = 10.0, 3.8 Hz, 1H), 3.90 – 3.64 (m, 1H), 3.28 – 3.10 (m, 3H), 2.95 (t, *J* = 12.9 Hz, 1H), 2.70 – 2.50 (m, 4H), 2.32 (td, *J* = 8.1, 4.2 Hz, 1H), 2.23 – 2.12 (m, 1H), 1.89 – 1.78 (m, 1H), 1.68 – 1.60 (m, 1H), 1.57 – 1.30 (m, 4H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  177.5, 175.5, 173.6, 170.4, 158.9, 148.1, 147.8, 136.0, 134.9, 134.4, 134.0, 133.5, 133.2, 132.4, 132.3, 131.6, 131.5, 131.4, 129.0, 128.9, 128.8, 128.6, 128.54, 128.51, 128.47, 128.2, 128.1, 124.4, 123.8, 72.8, 69.0, 67.6, 61.4, 59.0, 45.2, 41.6, 32.1, 30.0, 29.7, 28.1, 26.9, 23.8; IR (neat) v<sub>max</sub> 2931, 1737, 1544, 1372, 1155, 755 cm<sup>-1</sup>; HRMS (ESI): [M-H]<sup>-</sup> calculated for C<sub>49</sub>H<sub>50</sub>N<sub>5</sub>O<sub>18</sub>S<sub>2</sub> : 1060.2598, found: 1060.2641; [ $\alpha$ ]<sup>22</sup> – 14.2 (*c* 1.5, CHCl<sub>3</sub>); R<sub>f</sub> = 0.35 (DCM/MeOH = 10/1); m.p. = 102-105 °C.

#### Compound 15b




To a solution of diacid **20b** (40 mg, 0.038 mmol, 1 eq) in DCM (3.8 mL) was added anisole (61  $\mu$ L, 0.564 mmol, 15 eq) and trifluoromethanesulfonic acid (33  $\mu$ L, 0.380 mmol, 10 eq) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h, then warmed to room temperature, and stirred for 2 h. The reaction was quenched with a solution of NaHCO<sub>3</sub> (32 mg, 0.380 mmol, 10 eq) in water (5 mL) at 0 °C and stirred for an additional 0.5 h. The mixture was washed with DCM (10 mL x 3) and the water phase was concentrated *in vacuo* and directly used for the next step without further purification. The crude mixture and K<sub>2</sub>CO<sub>3</sub> (42 mg, 0.301 mmol, 8 eq) were dissolved in dry DMF (2 mL) and to this solution was added thiophenol (77  $\mu$ L, 0.752 mmol, 20 eq), and the reaction was stirred for 14 h at room temperature before water (10 mL) was added and washed with DCM (10 mL x 3). Then the water phase was concentrated *in vacuo*. The resulting solid was purified by gel column to afford **15b** (10 mg, 0.027 mmol, 72 %) as a white solid.

<sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 3.55 (t, J = 6.0 Hz, 1H), 3.36 – 3.21 (m, 3H), 3.11 – 2.88 (m, 3H), 2.40 – 2.17 (m, 2H), 2.12 – 1.81 (m, 6H), 1.76 – 1.63 (m, 2H), 1.53 – 1.34 (m, 2H); <sup>13</sup>C NMR (201 MHz, D<sub>2</sub>O) δ 182.1, 174.9, 62.6, 62.6, 62.3, 46.7, 39.0, 33.9, 30.0, 29.2, 28.6, 26.4, 21.4; IR (neat) v<sub>max</sub> 3381, 2945, 1577, 1399, 1033 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>15</sub>H<sub>28</sub>N<sub>3</sub>O<sub>8</sub> : 378.1871, found: 378.1858;

 $[\alpha]_{D}^{22}$  + 7.6 (c 0.65, H<sub>2</sub>O); m.p.>330°C.

#### Compound 18c




To a mixture of **S-2** (753 mg, 1.94 mmol, 1 eq) in THF (20 mL) and  $H_2O$  (20 mL) was added **S-3** (622 mg, 2.91 mmol, 1.5 eq), CuSO<sub>4</sub>·5H<sub>2</sub>O (1.46 g, 5.82 mmol, 3 eq) and Na ascorbate (1.15 g, 5.82 mmol, 3 eq) at r.t.. After stirring for 2 h, THF was removed, and the residue was diluted with EA (100 mL). The combined organic phases were washed with brine (20 mL x 2), dried with Na<sub>2</sub>SO<sub>4</sub>, and evaporated under *in vacuo*. The residue was further purified by silica gel column chromatography (DCM/EA = 10/1) to afford the desired product (1.12 g, 1.86 mmol, 96%) as colorless oil.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.04 - 7.93 (m, 1H), 7.76 - 7.71 (m, 1H), 7.64 - 7.55 (m, 2H), 7.31 - 7.25(m, 3H), 7.17 - 7.13(m, 2H), 6.66 (d, *J* = 8.8 Hz, 1H), 4.96 - 4.88 (m, 2H), 4.70 - 4.62 (m, 1H), 4.57 (dt, *J* = 8.8, 5.6 Hz, 1H), 4.27 (t, *J* = 7.0 Hz, 2H), 3.34 - 3.26 (m, 2H), 3.13 - 3.08 (m, 2H), 1.93 - 1.75 (m, 2H), 1.45 - 1.35 (m, 11H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.9, 156.0, 147.4, 134.7, 134.1, 133.4, 132.7, 130.2, 128.5, 128.4, 125.4, 122.4, 79.1, 67.5, 56.1, 49.8, 39.6, 29.4, 28.3, 27.3, 26.9; IR (neat)  $v_{max}$  3332, 2927, 1743, 1699, 1540, 1364, 1165, 742 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>35</sub>N<sub>6</sub>O<sub>8</sub>S: 603.2232, found: 603.2225; [α]<sub>2</sub><sup>21</sup> – 99.1 (*c* 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.15 (PE/EA = 1/1).


Compound 19c



Same procedure as the synthesis of **5a** to afford **19c** as white solid, yield = 96%.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.06 (d, *J* = 7.7 Hz, 1H), 7.90 (d, *J* = 7.8 Hz, 1H), 7.62 – 7.27 (m, 15H), 7.21 – 7.16 (m, 2H), 5.97 (d, *J* = 3.3 Hz, 1H), 5.53 (d, *J* = 3.4 Hz, 1H), 5.16 – 4.92 (m, 5H), 4.72 – 4.58 (m, 2H), 4.32 (t, *J* = 6.8 Hz, 3H), 3.76 – 3.58 (m, 1H), 3.54 – 3.40 (m, 2H), 3.30 (dd, *J* = 15.8, 10.9 Hz, 1H), 3.11 – 3.07 (m, 2H), 2.62 – 2.50 (m, 2H), 2.30 – 2.14 (m, 3H), 1.95 – 1.81 (m, 3H), 1.39 (s, 11H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.6, 169.6, 156.0, 148.4, 147.8, 142.8, 136.7, 134.9, 134.7, 134.2, 133.6, 133.3, 132.1, 131.8, 131.6, 131.5, 131.14, 131.05, 129.2, 128.59, 128.57, 128.53, 128.50, 128.5, 128.4, 123.8, 123.7, 122.4, 79.0, 67.8, 67.6, 66.2, 60.8, 57.6, 49.8, 45.2, 39.7, 33.6, 31.5, 29.1, 28.3, 27.4, 27.2, 26.9; IR (neat) v<sub>max</sub> 3417, 2928, 1739, 1706, 1543, 1370, 1163, 750 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>49</sub>H<sub>57</sub>N<sub>8</sub>O<sub>14</sub>S<sub>2</sub>: 1045.3430, found: 1045.3425; [ $\alpha$ ]<sub>5</sub><sup>21</sup> – 13.8 (c 1, CHCl<sub>3</sub>); R<sub>f</sub> = 0.30 (PE/EA = 1/2); m.p. = 65-68 °C.

Compound 20c



Same procedures as the synthesis of 14a to afford 20c as a white solid, yield = 54% for 2 steps.


<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN)  $\delta$  8.13 (d, *J* = 7.9 Hz, 1H), 7.84 (d, *J* = 7.6 Hz, 1H), 7.76 – 7.68 (m, 1H), 7.68 – 7.60 (m, 4H), 7.58 – 7.52 (m, 2H), 7.38 – 7.26 (m, 8H), 7.19 – 7.13 (m, 2H), 5.38 – 5.28 (m, 1H), 5.17 – 4.79 (m, 5H), 4.62 (dd, *J* = 9.8, 3.9 Hz, 1H), 4.52 – 4.42 (m, 1H), 4.31 (t, *J* = 6.8 Hz, 2H), 3.66 – 3.58 (m, 1H), 3.43 – 3.35 (m, 1H), 3.35 – 3.25 (m, 1H), 3.18 – 3.09 (m, 1H), 3.05 – 2.95 (m, 2H), 2.47 – 2.21 (m, 5H), 1.84 – 1.74 (m, 3H), 1.38 – 1.33 (m, 11H); <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>CN)  $\delta$  174.5, 172.0, 171.5, 170.4, 157.3, 149.2, 148.7, 143.5, 136.1, 136.0, 135.7, 135.4, 133.2, 132.8, 132.1, 132.0, 131.6, 129.7, 129.63, 129.56, 129.5, 129.4, 129.3, 125.0, 124.9, 124.3, 79.4, 68.9, 68.3, 62.4, 59.4, 58.3, 50.7, 46.1, 40.3, 33.2, 31.4, 28.6, 28.0, 27.6, 27.4, 26.9; IR (neat) v<sub>max</sub> 2925, 2852, 1731, 1544, 1370, 1261, 1165, 754 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>49</sub>H<sub>57</sub>N<sub>8</sub>O<sub>18</sub>S<sub>2</sub>: 1109.3227, found: 1109.3195; [α]<sub>0</sub><sup>21</sup> + 7.4 (c 1, CHCl<sub>3</sub>); m.p. = 112 - 115 °C.

#### Compound 15c



Same procedures as the synthesis of **2** to afford **15c** as a white solid, yield = 78% for 2 steps. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O)  $\delta$  7.85 (s, 1H), 4.45 (t, *J* = 6.5 Hz, 2H), 3.66 (t, *J* = 5.8 Hz, 1H), 3.38 (dd, *J* = 9.0, 4.1 Hz, 1H), 3.33 (t, *J* = 5.9 Hz, 1H), 3.27 - 3.11 (m, 3H), 3.02 - 2.91 (m, 3H), 2.37 - 2.23 (m, 2H), 1.97 (dt, *J* = 15.5, 7.8 Hz, 6H), 1.59 (d, *J* = 7.6 Hz, 2H); <sup>13</sup>C NMR (126 MHz, D<sub>2</sub>O)  $\delta$  181.9, 177.4, 176.8, 176.3, 143.0, 124.3, 62.9, 62.7, 62.6, 49.6, 46.2, 38.8, 33.9, 29.0, 28.5, 27.5, 26.4, 23.7; IR (neat)  $v_{max}$  3411, 1554, 1397, 1102, 996, 829 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>31</sub>N<sub>6</sub>O<sub>8</sub>: 459.2198, found: 459.2198; [ $\alpha$ ] <sup>21</sup>/<sub>2</sub> + 9.8 (*c* 0.5, H<sub>2</sub>O); m.p. > 330 °C.

#### Compound 16



Scheme S6: Syntheses of the pseudopaline-fluorescein probe.

To a solution of **15c** (5.6 mg, 12.3  $\mu$ mol, 1 eq) in water (1 mL) was added Et<sub>3</sub>N (8.5  $\mu$ L, 61.5  $\mu$ mol, 5 eq) and **S-4** (4.8 mg, 12.3  $\mu$ mol, 1 eq) at r.t.. After stirring for overnight at r.t., The reaction mixture was subjected directly to prep-HPLC (20% acetonitrile in 0.02% HCl in H<sub>2</sub>O for 3 min then a gradient of 20% – 90% acetonitrile in 0.02% HCl in H<sub>2</sub>O for 10 min) to afford the pure product **16** (2.3 mg, 2.71  $\mu$ mol, 22%) and the recovered **15c** (2 mg).

<sup>1</sup>H NMR (400 MHz,  $D_2O$ )  $\delta$  8.27 (s, 1H), 7.97 (s, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 9.8 Hz, 2H), 7.41 (d, J = 8.1 Hz, 1H), 7.35 (d, J = 2.0 Hz, 2H), 7.17 (dd, J = 9.2, 2.0 Hz, 2H), 4.48 (t, J = 5.6 Hz, 2H), 4.36 (d, J = 5.7 Hz, 1H), 4.12 (t, J = 6.4 Hz, 1H), 4.08 (t, J = 6.4 Hz, 1H), 3.64 – 3.56 (m, 2H), 3.50 – 3.38 (m, 4H), 2.72 – 2.57 (m, 2H), 2.48 – 2.33 (m, 2H), 2.29 – 2.16 (m, 2H), 2.03 – 1.93 (m, 2H), 1.65 – 1.56 (m, 2H); <sup>13</sup>C NMR (239 MHz,  $D_2O/$  CD<sub>3</sub>CN)  $\delta$  180.8, 176.2, 171.3, 170.8, 170.2, 168.7, 166.0, 156.7, 141.0, 140.7, 131.8, 129.8, 129.6, 128.5, 124.9, 117.3, 114.4, 102.9, 100.0, 62.8, 60.3, 60.0, 59.0, 50.3, 44.0, 29.9, 27.1, 26.6, 25.5, 25.2, 25.1; IR (neat)  $v_{max}$  3209, 2292, 2851, 1608, 1393, 1115 cm<sup>-1</sup>; HRMS (ESI): [M+H]<sup>+</sup> calculated for C<sub>39</sub>H<sub>40</sub>N<sub>7</sub>O<sub>13</sub>S: 846.2410, found: 846.2440; [ $\alpha$ ]<sub>2<sup>1</sup></sub><sup>2+</sup> + 18.0 (c 0.05, H<sub>2</sub>O/ACN); m.p. > 330°C.

# III) Comparison of the synthetic and natural Fmoc-pseudopaline

Table S1:

<sup>1</sup> H NMR Comparison of the synthetic and natural Fmoc-pseudopaline					
<sup>1</sup> H NMR of Fm	<sup>1</sup> H NMR of Fmoc–pseudopaline				
Natural Fmoc-pseudopaline	Synthetic Fmoc-pseudopaline				
7.92 (t, <i>J</i> = 7.2, 3H)	7.92 (t, <i>J</i> = 7.2, 3H)				
7.73 (d, <i>J</i> = 7.2, 2H)	7.72 (d, <i>J</i> = 7.2, 2H)				
7.49 (t, <i>J</i> = 7.2, 3H)	7.48 (t, <i>J</i> = 7.2, 3H)				
7.41 (t, <i>J</i> = 7.2, 3H)	7.42 (t, <i>J</i> = 7.2, 3H)				
7.20 (s, 1H)	7.20 (s, 1H)				
4.94 (d, <i>J</i> = 5.2, 2H)	4.92 (d, <i>J</i> = 5.2, 2H)				
4.50 (t, <i>J</i> = 5.2, 1H)	4.49 (t, <i>J</i> = 5.2, 1H)				
3.90 (t, <i>J</i> = 5.6, 1H)	3.90 (t, <i>J</i> = 5.6, 1H)				
3.66–3.60 (m, 2H))	3.65–3.59 (m, 2H))				
3.25 (t, <i>J</i> = 7.2, 2H)	3.24 (t, <i>J</i> = 7.2, 2H)				
3.10 (d, <i>J</i> = 5.2, 2H)	3.09 (d, <i>J</i> = 5.2, 2H)				
2.46 (t, <i>J</i> = 7.2, 2H)	2.38 (t, <i>J</i> = 7.2, 2H)				
2.32–2.24 (m, 2H)	2.30–2.21 (m, 2H)				
2.15 –2.09 (m, 2H)	2.10 –2.08 (m, 2H)				

Table S2:

## <sup>13</sup>C NMR Comparison of the synthetic and natural Fmoc-pseudopaline


<sup>13</sup> C NMR of Fmoc–pseudopaline			
Natural Fmoc-pseudopaline	Synthetic Fmoc-pseudopaline		
180.2	180.3		
173.2	173.2		
172.2	172.2		
172.0	172.0		
149.0	149.0		
143.1	143.1		
141.0	141.0		
138.0	138.0		
136.2	136.2		
128.2	128.2		
127.5	127.5		
125.0	125.0		
120.2	120.2		
115.6	115.6		
69.4	69.4		
62.8	62.8		
61.6	61.6		
59.9	59.8		
46.4	46.4		
43.5	43.5		
32.7	32.8		
27.4	27.4		
26.8	26.8		
26.4	26.5		

Table S3:


#### $[\alpha]_{D}^{20}$ Comparison of the synthetic and natural Fmoc-pseudopaline

	Natural Fmoc-pseudopaline	Synthetic Fmoc-pseudopaline
[a] <sup>20</sup>	+15 ( <i>c</i> 0.1, H <sub>2</sub> O)	+18 ( <i>c</i> 0.1, H <sub>2</sub> O)


<sup>1</sup>H NMR Comparison of synthetic and natural Fmoc-pseudopaline




## <sup>13</sup>C NMR Comparison of synthetic and natural Fmoc-pseudopaline





HRMS Comparison of synthetic and natural Fmoc-pseudopaline  $[M\text{+}H]^{\scriptscriptstyle +}$ 














## **IV) Biological Evaluations**



**Fig. S1** Pseudopaline had no influence on the uptake of  $Mn^{2+}$ ,  $Cu^{2+}$ ,  $Ca^{2+}$  and  $Mg^{2+}$  in *P. aeruginosa*. Intracellular manganese, copper, magnesium or calcium contents of wild type *P. aeruginosa* grown in VBMM containing corresponding metal and 50  $\mu$ M EDTA and treated with or without 100  $\mu$ M pseudopaline was measured by ICP-MS from three independent trials. Error bars, mean  $\pm$  SD.



**Fig. S2** Pseudopaline could not promote metal uptake in nutrient-rich LB medium (A) or in the VBMM medium containing the corresponding metal but without EDTA (B). Intracellular zinc, cobalt, nickel or iron contents of wild type *P. aeruginosa* treated with or without 100 µM pseudopaline was measured by ICP-MS from three independent trials. Error bars, mean ± SD.



**Fig. S3 Pseudopaline-fluorescein conjugate (P-FL 16) could be transported into** *P. aeruginosa.* Fluorescence microscopy images of PAO1 and Δ*zrmA* treated with pseudopaline-fluorescein (P-FL **16**), and PAO1 treated with fluorescein (FL) for 15 min. The top pictures were taken at: ex. 493±20 nm/em. 516±20 nm. The bottom pictures were taken by light microscopy (bright phase). Scale bar: 20 µm.

#### Bacterial strain, growth condition and strain construction

Unless indicated, *P. aeruginosa* and *E. coli* were grown at 37 °C in LB medium. Gentamycin was used at 10 µg/ml for *E. coli*, while gentamycin was used at 30 µg/ml, and irgasan at 25 µg/ml for *P. aeruginosa*.

The pseudopaline receptor mutated strain  $\Delta zrmA$  was constructed according to Battistoni's paper.<sup>2</sup> An unmarked, nonpolar deletion strategy was used. Simply, the upstream and downstream regions of *zrmA* were amplified by primers Up-F (GCTCGGTACCCGGGGATCCGAAATGCAGCGGATCGAGC), Up-R (TAGTTCAGGGGGGAAATCGCACCAGAAAAG), and Dw-F (GCGATTTCCCCCCTGAACTACTGAGCCCTC), Dw-R (GACGGCCAGTGCCAAGCTTGAAGCGATCAGGAAATGCGT), overlapped, and ligated in plasmid pEX18Gm.<sup>3</sup> The recombinant plasmid was transferred to PAO1 by mating, and a double-crossover recombinant was isolated as previously described.<sup>3</sup> This generated strain  $\Delta zrmA$ , in which 1-2113 bp were deleted.

#### Inductively coupled plasma mass spectrometry (ICP-MS)

The intracellular metal concentration was detected according to Battistoni's method with slight modification.<sup>2</sup> Overnight *P. aeruginosa* culture was collected, washed with PBS twice, diluted in the VBMM medium containing 10  $\mu$ M ZnSO<sub>4</sub>, a cocktail of transition metals in trace amounts (0.1  $\mu$ M FeSO<sub>4</sub>, NiSO<sub>4</sub>, CoSO<sub>4</sub>, CuSO<sub>4</sub> and MnSO<sub>4</sub>) or 1  $\mu$ M MgSO<sub>4</sub> and CaCl<sub>2</sub> and supplied with 50  $\mu$ M EDTA. The intracellular metal contents were detected with or without 100  $\mu$ M pseudopaline or *epi*-pseudopaline. The intracellular metal contents were detected in LB medium with 50  $\mu$ M EDTA or VBMM medium without EDTA. The effect of pseudopaline analog **15a**, **15b**, or **15c** on metal uptake was detected in VBMM medium containing 10  $\mu$ M ZnSO<sub>4</sub> and 50  $\mu$ M EDTA. After grown for 18 h at 37 °C, 10 mL of bacterial cultures were collected, centrifuged at 8000 rpm for 5 min and then the pellet was washed with 10 mL of PBS with 1 mM EDTA twice and 10 mL PBS once to remove excess metals. After the OD<sub>600</sub> was measured, the cell pellet was dried overnight at 95 °C. The metal contents were determined by re-suspending the dried pellet with 5 mL absolute HNO<sub>3</sub>, heated at 140 °C for 3 h and then diluted with 15 mL water. The metal contents were analyzed by ICP-MS (PerkinElmer NexION<sup>TM</sup> 350x) operating in argon collision gas mode to remove possible interferences. The intracellular metal concentration was normalized by OD<sub>600</sub>.

#### Fluorescence Microscopy

The uptake of pseudopaline-fluorescein **16** was detected according to Mislin's method with slight modification.<sup>4</sup> Overnight culture of wild type *P. aeruginosa* PAO1 and pseudopaline receptor mutated  $\Delta zrmA$  were collected, washed with PBS twice, re-suspended in PBS, 100 fold diluted into VBMM medium, and grown at 37 °C for 6 h with shaking. The pseudopaline-fluorescein **16** and fluorescein (5-Carboxyfluorescein) were first incubated with zinc at a ratio of 1: 1 for 15 min at room temperature before addition to the cells. The zinc complexes of the pseudopaline-fluorescence **16** or fluorescence molecule were then added to 1 mL aliquots of bacterial culture to obtain a 10  $\mu$ M final concentration. The mixtures were then incubated at 37 °C for 15 min. Cells were pelleted, washed with PBS for five times, re-suspended in PBS and then the fluorescence intensity of the bacteria was detected using Infinite F200 PRO Reader

(TECAN) (ex. 485 nm; em. 535 nm). And the images of fluorescence microscopy were acquired on a Leica TCS SP8x with 100x oil immersion lens using the following filter set: ex. 493±20 nm and em. 516±20 nm.

## V) Chelation Experiments

The Metal-Chelation experiments were established referring to P. Arnoux and co-workers' work<sup>1</sup> and our previous work<sup>5</sup>. Fe(III) has a poor affinity for staphylopine at neutral pH reported in the same work<sup>1</sup>, so we just tested the affinity of Cu(II), Co(II), Ni(II), Zn(II), Mn(II) and Fe(II). And the same mass-response pattern was observed in ESI-MS tests which suggested the metal(II)-chelators were maintained in the whole processes, and no oxidation reaction was observed by ESI-MS, especially for Fe(II).

We also tested the ion intensity of apo-ligands and holo-ligands to establish maximize ion intensities prior to doing the competition and found they shared the similar ion intensity (always the level from  $10^8$  to  $10^9$ ) by ESI-MS under the conditions we had screened. Only the [M+H]<sup>+</sup> ions were collected to estimate the p $K_d$  values.

#### 1) Stability constant test

The lon intensities (measured by MS) of different metal-ligand complexes have strongly positive correlation to the concentrations of chelation complexes, which allows us to using ESI-MS to estimate the  $pK_d$  value of Pseudopaline-metal complexes by  $pK_d$  values of staphylopine complexes.<sup>1</sup> Stability constants for Pseudopaline-metal complexes were estimated by metal competition experiments with staphylopine by using ESI-MS. A mixture of Pseudopaline (Pseudopaline, *epi*-Pseudopaline, Pseudopaline analog **15c**) (100  $\mu$ M, presented as C<sub>(PSEU)</sub>=100  $\mu$ M), staphylopine (100  $\mu$ M, presented as C<sub>(STA)</sub>=100  $\mu$ M) and limited level of metal (80  $\mu$ M, each metal was tested in a different experiment, presented as C<sub>(M)</sub>=80  $\mu$ M) to create competition and the different lon intensity ratios (presented as R<sub>X</sub>) were observed by ESI-MS between metal complexes. The equations between equilibrium concentration of different species (presented as [X]) and dissociation constants of ligand – metal complex (presented as  $K_{d (M-X)}$ ) were established to estimate the  $K_d$  of Pseu. The equations were listed here:

Dissociation reactions in the mixture of different metal complexes:

M-PSEU = M + PSEU M-STA = M + STA

Equations between C<sub>x</sub> and [X]:

 $C_{(M)} = [M-STA] + [M-PSEU] + [M]$   $\approx [M-STA] + [M-PSEU]$   $C_{(PSEU)} = [M-PSEU] + [PSEU]$   $C_{(STA)} = [M-STA] + [STA]$ 

Equations between [X] and  $K_{d (M-X)}$ :

 $R_{X} = \frac{[M-STA]}{[M-PSEU]+[M-STA]}$  $[M-STA]=C(M)^{-}R_{x}, [M-PSEU]=C(M)-[M-STA]$ 

 $[STA]=C_{(STA)}-[M-STA], [PSEU]=C_{(PSEU)}-[M-PSEU]$ 

$$\begin{split} \mathcal{K}_{d (M-PSEU)} &= \frac{[PSEU][M]}{[M-PSEU]}, \quad \mathcal{K}_{d (M-STA)} = \frac{[STA][M]}{[M-STA]} \\ \mathcal{K}_{d (M-PSEU)} &= \frac{[PSEU][M-STA]}{[PSEU-M][STA]} \cdot \mathcal{K}_{d (M-STA)} \end{split}$$

When pseudopaline was replaced by other analogues, the equations still exist.

#### **General Procedures:**

A water solution of Metal salts (1mmol/L, 80  $\mu$ L) was added to a mixture of Pseu solution (100  $\mu$ L, 1mmol/L), Sta solution (100  $\mu$ L, 1mmol/L) and then diluted with 720  $\mu$ L water. The obtained solution was allowed to shake for half an hour at room temperature to get a full chelation to get Pseudopaline-Metal complex and Sta-Metal complex. Then 200  $\mu$ L of the solution was diluted by 200  $\mu$ L methanol and 4  $\mu$ L formic acid, and the mixture was directly injected to the mass spectrum to observe the different lon intensity ratios of Pseu-Metal complex and Sta-Metal complex and for two times.

## Results:

Table S4: Ion intensity Data for Pseu-M(II) complexes and Sta-M(II) complexes.

Metal	I <sub>1(Sta-M)</sub>	I <sub>1(PSEU -M)</sub>	I <sub>2(Sta-M)</sub>	I <sub>2(PSEU-M)</sub>
Cu <sup>2+</sup>	1.11×10 <sup>10</sup>	1.91×10 <sup>10</sup>	5.56×10 <sup>9</sup>	1.07×10 <sup>10</sup>
Ni <sup>2+</sup>	3.88×10 <sup>9</sup>	4.82×10 <sup>9</sup>	3.63×10 <sup>9</sup>	4.93×10 <sup>9</sup>
Co <sup>2+</sup>	1.80×10 <sup>9</sup>	7.21×10 <sup>9</sup>	1.39×10 <sup>9</sup>	5.24×10 <sup>9</sup>
Zn <sup>2+</sup>	9.9×10 <sup>8</sup>	2.76×10 <sup>9</sup>	5.85×10 <sup>8</sup>	1.75×10 <sup>9</sup>
Fe <sup>2+</sup>	2.64×10 <sup>8</sup>	1.15×10 <sup>9</sup>	2.62×10 <sup>8</sup>	1.13×10 <sup>9</sup>
Mn <sup>2+</sup>	8.82×10 <sup>8</sup>	5.90×10 <sup>9</sup>	5.10×10 <sup>8</sup>	3.52×10 <sup>9</sup>

## I: Ion intensity

Table S5:  $pK_d$  values of Pseudopaline-metal complexes.

Metal	R <sub>aver</sub>	р <i>К</i> d (Sta)	Kd (PSEU)	pKd(PSEU)
Cu <sup>2+</sup>	0.342	19.0	3.72×10 <sup>-20</sup>	19.42
Ni <sup>2+</sup>	0.435	16.4	2.58×10 <sup>-17</sup>	16.59
Co <sup>2+</sup>	0.204	15.1	8.89×10 <sup>-17</sup>	15.1
Zn <sup>2+</sup>	0.257	15.0	1.77×10 <sup>-16</sup>	15.75
Fe <sup>2+</sup>	0.197	12.3	7.24×10 <sup>-14</sup>	13.14
Mn <sup>2+</sup>	0.128	9.1	3.94×10 <sup>-11</sup>	10.40

## Table S6: Ion intensity Data for epi-Pseudopaline-M(II) and Sta-M(II) complexes.

Metal	I <sub>1(Sta-M)</sub>	I <sub>1(epi-Pseu</sub> -M)	I <sub>2(Sta-M)</sub>	I <sub>2(epi-Pseu-M)</sub>
Cu <sup>2+</sup>	1.36×10 <sup>9</sup>	3.26×10 <sup>9</sup>	1.91×10 <sup>9</sup>	4.36×10 <sup>9</sup>
Ni <sup>2+</sup>	3.41×10 <sup>9</sup>	4.64×10 <sup>9</sup>	2.66×10 <sup>9</sup>	3.66×10 <sup>9</sup>
<b>Co</b> <sup>2+</sup>	8.24×10 <sup>8</sup>	6.45×10 <sup>8</sup>	8.06×10 <sup>8</sup>	6.04×10 <sup>8</sup>
Zn <sup>2+</sup>	3.91×10 <sup>8</sup>	2.78×10 <sup>9</sup>	6.15×10 <sup>8</sup>	4.20×10 <sup>9</sup>
Fe <sup>2+</sup>	4.84×10 <sup>8</sup>	1.09×10 <sup>9</sup>	3.75×10 <sup>8</sup>	8.60×10 <sup>8</sup>
Mn <sup>2+</sup>	1.37×10 <sup>9</sup>	1.85×10 <sup>9</sup>	6.91×10 <sup>8</sup>	9.87×10 <sup>8</sup>

## I: Ion intensity

Table S7:  $pK_d$  values of *epi*-Pseudopaline-metal complexes.

Metal	Raver	р <i>К</i> d ( Sta )	Kd ( epi-Pseu )	$pK_{d(epi-Pseu)}$
Cu <sup>2+</sup>	0.299	19.0	2.47×10 <sup>-20</sup>	19.60
Ni <sup>2+</sup>	0.422	16.4	2.36×10 <sup>-17</sup>	16.62
Co <sup>2+</sup>	0.566	15.1	1.24×10 <sup>-15</sup>	14.90
Zn <sup>2+</sup>	0.589	15.0	1.82×10 <sup>-15</sup>	14.73
Fe <sup>2+</sup>	0.306	12.3	1.30×10 <sup>-13</sup>	12.89
Mn <sup>2+</sup>	0.419	9.1	4.60×10 <sup>-10</sup>	9.34

## Table S8: Ion intensity Data for 15c-M(II) complexes and Sta-M(II) complexes.


8c-M)
8×10 <sup>9</sup>
×10 <sup>10</sup>
8×10 <sup>9</sup>
5×10 <sup>9</sup>
8×10 <sup>9</sup>
)×10 <sup>8</sup>


I: Ion intensity


Table S9:  $pK_d$  values of Pseudopaline-**15c**-metal complexes.


Metal	Raver	р <i>К</i> d ( Sta )	Kd ( PSEU )	$pK_{d(PSEU)}$
Cu <sup>2+</sup>	0.410	19.0	5.46×10 <sup>-20</sup>	19.26
Ni <sup>2+</sup>	0.300	16.4	9.9×10 <sup>-18</sup>	17.01
Co <sup>2+</sup>	0.297	15.1	1.93×10 <sup>-16</sup>	15.72
Zn <sup>2+</sup>	0.410	15.0	3.34×10 <sup>-16</sup>	15.47
Fe <sup>2+</sup>	0.193	12.3	5.01×10 <sup>-14</sup>	13.30
Mn <sup>2+</sup>	0.243	9.1	1.98×10 <sup>-10</sup>	9.70


## VI) <sup>1</sup>H and <sup>13</sup>C NMR spectra





























































888,000 89,000 89,000 89,000 89,000 89,000 89,000 80,00
























210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm)









## Comparison of synthetic and natural Fmoc-pseudopaline <sup>1</sup>H NMR comparison of synthetic and natural Fmoc-pseudopaline




<sup>13</sup>C NMR comparison of synthetic and natural Fmoc-pseudopaline




HRMS comparison of synthetic and natural Fmoc-pseudopaline  $[\text{M}\text{+}\text{H}]^{\text{+}}$ 







[M-H]<sup>-</sup> Intens. x10<sup>8</sup> FTMS-18040233\_Neg\_20180425\_000001.d: -MS 607.20466 0.8 0 .OH 0.> \_OH -NFmoc 0.6 Ň но 608.20950 natural Fmoc-pseudopaline 0.4 0.2 610.20156 609.21325 603.99515 0.0 604 606 612 605 607 608 609 610 611 m/z 
 Meas.m/z
 # Ion Formula
 Score
 m/z
 err [ppm]
 Mean err [ppm]
 mSigma
 rdb
 e<sup>-</sup> Conf
 N-Rule


 607.204664
 1
 C30H31N4O10
 100.00
 607.204567
 -0.2
 -1.6
 74.0
 17.0
 even
 ok





## <sup>1</sup>H and <sup>13</sup>C NMR spectra of analogs 15a, 15b, and 15c





































# **VII) HRMS Data for Chelation Experiments**

#### 1) Pseudopaline-Metal complexes and Staphylophine complexes


 $[M+H]^{+}$  of [M-Sta] was calculated as  $C_{13}H_{19}N_4O_6M$   $[M+H]^{+}$  of [M-Pseu] was calculated as  $C_{15}H_{21}N_4O_8M$ 


1.1 Pseudopaline-Cu Complexes and Staphylophine-Cu Complexes






#### 1.2 Pseudopaline-Ni Complexes and Staphylophine-Ni Complexes







## 1.3 Pseudopaline-Co Complexes and Staphylophine-Co Complexes




Analysis Info				
Analysis Name Sample Comment	FTMS-18080008_Pos wss-0495-Co	s_20180809_000001.d	Acquisition Date Instrument Operator	8/9/2018 4:37:09 PM Bruker Solarix XR FTMS Peking University
intens x10 <sup>9</sup>		387.15062	F	FMS-18080008_Pos_20180809_000001.d: +
5-				
4				
3-				
2-				
1 337.97201		386.06310 399.15107	444.06868	
0 344.	369.14038 00972 360	380 400	425.10697 420 440 460	480 500

#### 1.4 Pseudopaline-Zn Complexes and Staphylophine-Zn Complexes






## 1.5 Pseudopaline-Fe Complexes and Staphylophine-Fe Complexes



Analysis Info										
Analysis Name Sample Comment	FTMS-18080087_Pos_20180820_000001.d wss-0496-SP-Fe					Acquisition Date Instrument Operator	E	8/20/2018 2:21:34 PM Bruker Solarix XR FTMS Peking University		
Intens. ×10 <sup>9</sup>		387	15099					FTMS-180800	187_Pos_20180820	0_000001.d: 4
1.25-										
1.00-										
0.75										
0.50										
0.25-	369.14046		1 3	99.15108						
0.00	360	383.0650	202.0266	1	409.13302	425.097	97 441.0705	449.06459	460	471.10521

# 1.6 Pseudopaline-Mn Complexes and Staphylophine-Mn Complexes





Analysis Info										
Analysis Name Sample Comment	FTMS-18 wss-0495		20180809	_000001.d			Acqui Instru Opera		8/9/2018 4:47: Bruker Solarix Peking Univer	XR FTMS
intens. ×10 <sup>91</sup>								FTMS	5-18080010_Pos_201808	09_000001.d: +f
			387.15	061						
4										
-										
3-										
1										
2-										
1-			382.06799	399.1511						
0	6 351.13059	369.14038			1	425.10699	440.07365			
340	360		380	400	 4	20	440	460	480	500 r

#### 2) Pseudopaline-Metal complexes and Staphylophine complexes


 $[M+H]^+$  of [M-Sta] was calculated as  $C_{13}H_{19}N_4O_6M$   $[M+H]^+$  of [M-epi-Pseu] was calculated as  $C_{15}H_{21}N_4O_8M$ 


2.1 epi-Pseudopaline-Cu Complexes and Staphylophine-Cu Complexes







#### 2.2 epi-Pseudopaline-Ni Complexes and Staphylophine-Ni Complexes






#### 2.3 epi-Pseudopaline-Zn Complexes and Staphylophine-Zn Complexes







### 82

#### 2.4 epi-Pseudopaline-Co Complexes and Staphylophine-Co Complexes







#### 2.5 epi-Pseudopaline-Fe Complexes and Staphylophine-Fe Complexes



Analysis Info Analysis Name Sample	FTMS-1808008 wss-0496-SE-Fe	8_Pos_20180820_00	Acquisitio		8/20/2018 2:28:25 PM Bruker Solarix XR FTMS			
Comment							Peking University	
Intens.						FTMS-18	080088_Pos_20180820_00	0001.d; +
×10 <sup>8</sup>	387.15102							
6-								
1								
1								
2-								
			409.13299					
1						441.0	7063	
	383.06491 39	398.24140	404 03894	419 0416	3 425.10714 431.114	95	449.09488	
ب ب العبدان	380 3	90 400	410	420	· · · · · · · · · · · · · · · · · · ·	440	450	


#### 2.6 epi-Pseudopaline-Mn Complexes and Staphylophine-Mn Complexes







#### 3) 15c-Metal complexes and Staphylophine complexes

 $[M+H]^+$  of [M-Sta] was calculated as  $C_{13}H_{19}N_4O_6M$  $[M+H]^+$  of [M-Pseu-linker] was calculated as  $C_{15}H_{21}N_4O_8M$ **3.1 15c-Cu Complexes and Staphylophine-Cu Complexes** 







## 3.2 15c-Ni Complexes and Staphylophine-Ni Complexes




Analysis Info											
Analysis Name Sample Comment	FTMS-180800 wss-0496-SZ-	74_Pos_2018082 Ni	20_000001.d				Acqui Instru Opera		Bruker	18 11:54:06 AN Solarix XR FTM University	
intens. ×10 <sup>9</sup>								FTMS	-18080074_Pos	_20180820_00000	1.d: +i
×10-					459.	21989					
-											
1.5-											
1									515.43962		
1.0											
1.0-											
1				441.2092	5						
0.5-	385.06525										
	I		31568				481.20197			537.12173	
0.0 360	380	407.04726	120	440		460	480	497.16701	520	540	<u>.,,</u>


#### 3.3 15c-Zn Complexes and Staphylophine-Zn Complexes







#### 3.4 15c-Co Complexes and Staphylophine-Co Complexes







#### 3.5 15c-Fe Complexes and Staphylophine-Fe Complexes





#### 3.6 15c-Mn Complexes and Staphylophine-Mn Complexes






## 91


## VIII) X-ray crystal structures

1. Crystal data and X-ray structure refinement for 14c (CCDC 1850196):



Flack parameter -0.03(2)

2. Crystal data and X-ray structure refinement for 20b (CCDC 1863986):



## Crystal data and structure refinement for 20b.

,	
Identification code	Compound 20b
Empirical formula	$C_{51}H_{53}CI_6N_5O_{18}S_2$
Formula weight	1300.80
Temperature/K	180.00(10)
Crystal system	monoclinic
Space group	P2 <sub>1</sub>
a/Å	14.5442(2)
b/Å	14.2345(2)
c/Å	14.7460(2)
α/°	90
β/°	106.978(2)
γ/°	90
Volume/Å <sup>3</sup>	2919.80(8)
Z	2
ρ <sub>calc</sub> g/cm <sup>3</sup>	1.480
µ/mm <sup>-1</sup>	0.441
F(000)	1344.0
Crystal size/mm <sup>3</sup>	0.25 × 0.12 × 0.08

Radiation	Μο Κα (λ = 0.71073)
2O range for data collection/°	4.066 to 54.97
Index ranges	$-18 \le h \le 18,  -18 \le k \le 18,  -19 \le l \le 19$
Reflections collected	68502
Independent reflections	13403 [ $R_{int} = 0.0329$ , $R_{sigma} = 0.0287$ ]
Data/restraints/parameters	13403/2/738
Goodness-of-fit on F <sup>2</sup>	1.039
Final R indexes [I>=2o (I)]	R <sub>1</sub> = 0.0552, wR <sub>2</sub> = 0.1421
Final R indexes [all data]	$R_1 = 0.0611, wR_2 = 0.1458$
Largest diff. peak/hole / e Å-3	0.83/-0.75
Flack parameter	0.002(11)

# **IX)** References

(1) G. Ghssein, C. Brutesco, L. Ouerdane, C. Fojcik, A. Izaute, S. Wang, C. Hajjar, R. Lobinski, D. Lemaire, P. Richaud, R. Voulhoux, A. Espaillat, F. Cava, D. Pignol, E. B. Durant, P. Arnoux, Science 2016, 352, 1105–1109.

(2) M. C. Mastropasqua, M. D'Orazio, M. Cerasi, F. Pacello, A. Gismondi, A. Canini, L. Canuti, A. Consalvo, D. Ciavardelli, B. Chirullo, P. Pasquali, A. Battistoni, *Mol. Microbiol.* **2017**, *106*, 543-561.

(3) T.T. Hoang, R. R. Karkhoff-Schweizer, A. J. Kutchma, H. P. Schweizer, *Gene.* **1998**, *212*, 77-86.

(4) S. Noël, L. Guillon, I. J. Schalk, G. t. L. Mislin, *Org. Lett.* **2011**, *13*, 844–847.

(5) J. Zhang, S. Wang, Y. Bai, Q. Guo, J. Zhou, X. Lei, J. Org. Chem. 2017, 82, 13643-13648.